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Dedication
This dissertation is dedicated to Anne Watson Kiefer who passed on August 8,
2007 at the age of one hundred and two years old. A native of Scotland, Grandma Kiefer
grew up during the time of horse-drawn carriages and lived to see man’s first flight, two
World Wars, the invention of the computer, and the arrival of the Space Age. Her life
was long and well lived and she will be missed this May at my graduation ceremony.

Facile credo, plures esse Naturas invisibiles quam visibiles in rerum universitate. Sed
horum omnium familiam quis nobis enarrabit? et gradus et cognationes et discrimina et
singulorum munera? Quid agunt? quae loca habitant? Harum rerum notitiam semper
ambivit ingenium humanum, nunquam attigit. Juvat, interea, non diffiteor, quandoque in
animo, tanquam in tabula, majoris et melioris mundi imaginem contemplari: ne
mensassuefacta hodiernae vitae minutiis se contrahat nimis, et tota subsidat in pusillas
cogitationes. Sed veritati interea invigilandum est, modusque servandus, ut certa ab
incertis, diem a nocte, distinguamus.
T. Burnet, Archaeol. Phil. p. 68*

*Translation: I readily believe that in the totality of things there are more invisible than
visible natures. But who shall recount to us the family of all these things? And their
degrees and relationships and distinctive signs and their individual functions? What do
they do? What places do they inhabit? The human mind has always solicited knowledge
of these matters but has never attained it. Meanwhile, I do not deny, it is sometimes
pleasant to contemplate the image of a greater and better world in the mind as if in a
picture, lest the mind, accustomed to the trivia of modern life, should shrink excessively
and sink completely into petty musings. But at the same time one must be intent upon
truth, and moderation must be observed, so that we may distinguish the sure from the
unsure, day from night.
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Abstract
Chapter 1 contains an introduction to porphyrins and carboranylporphyrins, including
their physical properties, history, methods of synthesis, medicinal applications, and an
overview of recently published compounds. Chapter 2 contains the total synthesis of a
series of trimethylamine- and phosphonate-substituted carboranylporphyrins for
application in boron neutron capture therapy (BNCT), including characterization by
proton nuclear magnetic resonance spectroscopy, matrix-assisted time-of-flight mass
spectroscopy, high resolution mass spectroscopy, UV-Vis spectrophotometry, X-ray
crystallography, and melting point apparatus. Chapter 3 contains synthetic methods
which were investigated as alternate routes to porphyrin synthesis and functionalization.
Chapter 4 presents the in vitro biological evaluation of trimethylamine- and phosphonatesubstituted carboranylporphyrins.
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Chapter 1
Introduction
1.1 Porphyrins: Pigments of Life
From the red copper complex of uroporphyrin-III 1.1 found in the wing feathers of the
Hoatzin (Turacus indicus), a long-tailed, crested bird that inhabits the riverbank lowlands
of South America1 to the iron(II) complex of protoporphyrin-IX, heme 1.2, responsible
for the oxygen-transportation and storage functions within the hemoglobins and
myoglobins of our own red blood cells, porphyrins are ever-present and play a vital role
in the maintenance of life on Earth. All plant life depends upon the light-harvesting
properties of chlorophyll-a 1.3, a porphyrin derivative Figure 1-1. Porphyrins can be
found in B-12 vitamins and the peroxidase and catalase enzymes of both animal and plant
tissues.

The proteins of cytochromes involved in electron transport within the

mitochondria of cells contain porphyrins. For these reasons, porphyrins have been called
2

the “pigments of life” and their importance makes them essential molecules of scientific
inquiry.
1.2 Physical Properties of Porphyrins
A porphyrin 1.4 is a tetrapyrrolic macrocycle joined by four bridging methines and
possessing a 22-π electron count with an 18-π electron aromatic structure. These 18-π
electrons allow for six different delocalized pathways, according to Scheme 1-1, which
obey Huckel’s (4n + 2) Rule for aromatic systems. Characteristic of all porphyrins with
this π-system is a distinct UV-Vis absorption at approximately 420 nm called the Soret
band. Four additional, lesser absorptions occur between 500 – 700 nm and are referred to
as Q-bands. Substituents placed at the beta-positions of the pyrroles or at the mesopositions around the macrocycle will slightly shift these Soret and Q-bands, but as long

1

COOH

HOOC

HOOC

N

N

COOH

N

COOH

Cu
N

HOOC

COOH
HOOC
Uroporphyrin-III 1.1
Me

Me

Me
N

Me

N
Fe

N
Me

N

N
Mg

N
H
Me

Me

N

N

H
H
O
O
O PhytylCO2Me
Chlorophyll-a 1.3

COOH
HOOC
Heme 1.2

Figure 1-1: Naturally Occurring Porphyrins
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Scheme 1-1: Six different 18-! electron aromatic pathways of the porphyrin macrocycle

as the 18-π system remains intact, the aforementioned bands will be observed.3 Because
of its aromatic, macrocyclic structure, porphyrins exhibit an anisotropic effect.4-6 Ring
currents shield the inner pyrrolic protons, resulting in a marked shift upfield between (-2
to -4) ppm. Conversely, the beta-pyrrolic and meso protons are deshielded and are
observed downfield circa (8-9) ppm in their 1H-NMR spectra. Porphyrins are amphoteric,
meaning the inner pyrrolic nitrogens exhibit acidic and basic properties with the
following pKas: pK4 = 0.5-4, pK3 = 3-6, pK2 = 13-16, and pK1 = 15-16.7 The protonation
or deprotonation of the tetrapyrrole is sometimes accompanied by an observable color
change. The metalation of the inner pyrrolic nitrogens is easily accomplished and may
cause the porphyrin to assume a more planar D4h symmetry. While basic unsubstituted
metalloporphyrins are D4h in their symmetry, substituents added at the peripheral
positions may cause the porphyrin to bend out of its planarity. Common derivatizations
at the meso and β-positions include nitration, sulfonation, cyanation, formylation,
deuteration, acylation, and halogenation.

3

1.3 The 19th Century and Early 20th Century History of Porphyrins8
The history of porphyrins begins almost two centuries ago when, in 1818, Pelletier and
Caventou9 first used the word chlorophyll, a reduced form of porphyrin, to describe the
green pigment of leaves. In 1844 Verdeil suggested a relationship between chlorophyll
and heme upon chemical conversion of chlorophyll to a red pigment.10 The first
porphyrin was isolated in 1867 by Thudichum11 who treated hemoglobin (cruorin at that
time) with sulfuric acid and extracted it with alcohol.

He called his porphyrin

"cruentine," commonly known today as hematoporphyrin. Thudichum was ridiculed at
the time by Hoppe-Seyler but, in 1884 when Nencki12 obtained a pure sample of
hematoporphyrin hydrochloride from isolated hemin, Thudichum’s original discovery
was confirmed. The original work on porphyrin-containing cytochromes is credited to
MacMunn13 who, in 1886, described myohematin and histohematin. It would not be until
1925, however, that Keilin14 would rediscover MacMunn’s earlier work and publish it.
In 1883 Soret15 observed the first spectroscopic evidence of a strong electronic
absorption at 420 nm in the UV-Vis spectra of hemoglobin. This absorption band is
typical of all porphyrins and is referred to today as the Soret band. The correct structure
of a porphyrin was not proposed until the early 20th century when Kuster, in 1912,
proposed a tetrapyrrolic macrocyclic structure.16 This structure did not gain widespread
acceptance, however, and debate persisted when, in 1913, Willstatter proposed an
alternative tetrapyrrylethylene structure.17 Several years would pass before Hans Fisher,
in 1926, synthesized octamethylporphyrin18 and the type I, II, and III isomers of
etioporphyrin.

19

In doing so he demonstrated the validity of Kuster's earlier proposed

4

structure and for his pioneering efforts was awarded the Nobel Prize for Chemistry in
1930.
1.4 Syntheses of Porphyrins
A comprehensive summary of the various methods of porphyrin syntheses is beyond the
scope of this chapter. Those interested in a complete review of the subject can look
elsewhere.20 For the purpose here I summarize below four synthetic methods which
encompass the development of methods to make porphyrins: Rothemund and Menotti,
Adler and Longo, Lindsey, and MacDonald.
R
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+

CHO pyridine
MeOH
R
150oC
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R
11%
R=H

NH
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N
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R
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Scheme 1-2: Synthesis of TPP using Rothemund conditions

Rothemund and Menotti synthesized 5,10,15,20-tetraphenylporphyrin (TPP) 1.7 at high
temperature by the reaction of benzaldehyde 1.6 and pyrrole 1.5 in a sealed tube.21, 22
Pyridine was used as the solvent in the reaction, and the highest yield of TPP obtained
was 11% (Scheme 1-2). A better yield was achieved when the reaction took place in the
presence of Zn(OAc)2 at high pressure. Due to the harsh reaction conditions, the
Rothemund method is compatible with only a very few substituted benzaldehydes.

5

Twenty-five years after the Rothemund conditions were developed, Adler and Longo
investigated the synthesis of porphyrins under a new set of relatively mild conditions
Scheme 1-3. TPP 1.7 was formed by refluxing pyrrole 1.5 and benzaldehyde 1.6 in
propionic acid.23 Reaction rates were faster using the Adler-Longo method and produced
TPP in a higher yield of 20% compared to the Rothemund yield of 11%.
These milder conditions also allowed for the synthesis of porphyrins with a wider
variety of substituents, though more acid-sensitive functional groups were not compatible
with this method. One problem associated with the Adler-Longo method is the formation
of large amounts of tar. Purifications can be problematic because of the difficulty in
removing the tar. Though more modern synthetic methods have been developed, the
syntheses of meso-tetraarylporphyrins using the Adler-Longo method remains the most
efficient when the target porphyrins can be easily separated (e.g. upon precipitation from
a cold propionic acid solution).

R

CHO
N
H
1.5

NH

H3CCH2CO2H
R
O2, 141 oC

N
R

N

HN

R
R=H
1.6
R
1.7
Scheme 1-3: Synthesis of TPP using Adler-Longo conditions.

6

The synthesis of TPP and related porphyrins was greatly advanced in 1987 by Lindsey
and coworkers24 who demonstrated that TPP could be formed under equilibrium
conditions (Scheme 1-4). Furthermore, it was shown that many functional groups could
be tolerated under these conditions. Under Lindsey conditions a colorless porphyrinogen
product is formed, followed by oxidation with, for example, p-chloranil or DDQ to yield
the porphyrin. Use of p-chloranil for the oxidation of the porphyrinogen typically gave
higher yields than with DDQ. The final porphyrin products were obtained in up to 55 %
yields, which was a dramatic improvement over the Adler-Longo or Rothemund
methods.
In the Lindsey method TPP 1.7 was formed by dissolving benzaldehyde 1.6 and
pyrrole 1.5 in a dilute (10-2 M) solution of dichloromethane. A Lewis acid catalyst
(BF3•Et2O or TFA) at a dilution of 10-3 M was then added to the reaction. Many factors
such as choice of oxidant, reaction time, concentration of starting materials, and catalyst
were found to affect the reaction. As in benzene chemistry, the nucleophilicity of the
pyrrole is governed by the type of substitution present on the ring. An electron-donating
group such as an alkyl group enhances the nucleophilicity of the pyrrole, while an
electron-withdrawing group such as an ester decreases the reactivity. Using UV-Vis
spectroscopy, Lindsey monitored the yields of TPP at various reaction times and
optimized the reaction conditions.
One problem in all porphyrin syntheses is the formation of polymeric species versus
cyclic species. It was found that the ratio of these products was not concentration
dependent. Also, the rate of oxidation was dependent on which oxidizing agent was

7

chosen. The use of DDQ yielded the TPP porphyrin within minutes, but the use of a
milder oxidizing agent such as p-chloranil yielded the porphyrin within an hour.

R

CHO
1) BF3 . OEt2
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R
NH +
2) p-chloranil
1 hr reflux
1.5
R
50-55 %
-2
10 mM
R=H

NH

N
R

N

1.6
10-2 mM

HN

R
1.7

Scheme 1-4: Synthesis of TPP using Lindsey conditions.

In addition to monopyrrole tetramerization, symmetrical and unsymmetrical
porphyrins 1.9 can be prepared by the condensation of two dipyrromethanes 1.8 with
either mixed or similar aldehydes 1.6. This is often referred to as the MacDonald [2+2]
method.25 An example of the MacDonald [2+2] reaction can be seen in Scheme 1-5. The
condensation shows that a symmetrical porphyrin can be produced from the condensation
of two similar dipyrromethanes and two similar aldehydes.
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Scheme 1-5: Synthesis of a 5,15-diaryl porphyrin using MacDonald [2 + 2]
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The main drawback with the MacDonald method is the scrambling of the
dipyrromethanes, resulting in the formation of many different porphyrin products. After
the initial protonation of the dipyrromethane by the acid catalyst, a highly reactive
intermediate is generated. Scheme 1-6 illustrates this mechanism. Despite this drawback
the development of methods such as the MacDonald [2+2] condensation has given rise to
the synthesis of many novel porphyrins and is the preferred method for the many
porphyrins produced in this dissertation.
1.5 Current Medicinal Uses Of Porphyrins
There are two current medicinal uses for porphyrins: photodynamic therapy (PDT) and
boron neutron capture therapy (BNCT). The following subsections will introduce these
two therapies and explain their mechanisms.
1.5.1 Photodynamic Therapy (PDT)
PDT is an established treatment for several malignant and pre-malignant conditions
including esophageal, skin, lung, bladder, head and neck, and invasive intracranial
tumors.26,

27

After intravenous injection, the PDT drug, or photosensitizer, selectively

accumulates in the neoplastic tissues without causing a cytotoxic response to neighboring
healthy tissues.

Once inside, the malignant tissues are irradiated with a specific

wavelength of light, causing the photosensitizer to initiate tumor necrosis through the
irreversible formation of a reactive oxygen species (ROS) such as singlet oxygen, super
oxide anion, and radical hydroxyl. It has been shown that optimal tissue penetration of
light occurs between 650-800 nm.
Scheme 1-7 illustrates a modified Jablonski diagram of the mechanism of PDT.28
Upon irradiation with a suitable wavelength of visible light, the photosensitizer is excited
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from its singlet ground state (P0) to an excited 1P* singlet state (1). The molecule can
return to its singlet ground state via a fluorescent release of energy (2), or it can undergo
a non-radiative transition (3) to an excited triplet state (3P*). If the photosensitizer
follows the first pathway, the tumor will fluoresce and be visible, or be revealed by
thermal detection. If the photosensitizer follows the second pathway, it will subsequently
undergo a process called phosphorescence (4).

Phosphorescence is measured in

microseconds and involves a spin-inversion or spin-forbidden pathway, allowing for an
Porphyrin Sensitizer

Oxygen

1P*_________

3
5

Energy

________ 3p*

1O __________
2

1

2
4
6

P0 __________________________
1.
2.
3.
4.
5.
6.

3O
2

__________

Absorption of Light
Fluorescence
Intersystem Crossing
Phosphorescence
Hydrogen radical or Electron Transfer
Singlet Oxygen Production

Scheme 1-7: Mechanism of Photodynamic Therapy (PDT)
interaction of the photosensitizer with molecules in the vicinity. One such molecule is
molecular oxygen, which is in abundance in tissues and also has a similar, triplet ground
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state. Cytotoxic particles are created from the molecular oxygen via two mechanistic
pathways. Type I mechanism (5) involves the transfer of a hydrogen radical or an
electron from the photosensitizer to molecular oxygen, thereby generating ions or free
radical species (peroxide anions and super oxide) which will target the tumor. Type II
mechanism (6) involves the direct interaction of the triplet state photosensitizer with the
triplet state molecular oxygen to produce electronically excited and highly cytotoxic,
singlet-state, oxygen species.29
Currently, there are two United States Food and Drug Administration (FDA)
approved, synthetically-prepared, porphyrin drug for PDT.

Photofrin, as it is

commercially known, is used for the treatment of patients with advanced stage lung
cancer and melanoma, as well as cancers of the digestive and genitourinary tract.30
Prepared initially in 1981 by Dougherty et al, Photofrin is something of an oddball drug.
To begin with, it is not prepared in pure form; rather, it is administered as a mixture of
porphyrins.

The pharmacokinetics and pharmacology of this mixture are not fully

understood and no one knows what the active form of the drug is.

Additionally,

Photofrin, is activated by visible light at 630 nm, below the previously stated ideal range
for deepest tissue penetration (650-800 nm) and is, therefore, not suited for deep
malignancies. An undesirable side effect of Photofrin is prolonged skin sensitivity due to
the lengthy cell retention time of the photosensitizer.31
Another FDA-approved drug called Visudyne, which is also a mixture, is synthetically
prepared by cycloaddition reactions and is successfully used in the treatment of macular
degeneration.32 As a consequence research in the last 20 years has focused on the

12

development of new porphyrin-based PDT photosensitizers that are more effective than
the current FDA-approved drugs.
1.5.2 Boron Neutron Capture Therapy (BNCT)
Porphyrins have been observed for nearly a century to selectively accumulate in the
neoplastic tissues of tumors.33 This observation has led present-day scientific researchers
to develop synthetic strategies that combine the porphyrin’s physiochemical properties of
low dark toxicity and high tumor selectivity with a carborane cage containing boron
atoms. An example which was prepared as part of this dissertation is compound 1.10.

Me

Me

NH
N

N
HN

Me

Me

= BH
=C
1.10
Porphyrin’s role in BNCT is to act as a carrier molecule for carborane clusters, delivering
a high concentration of

10

B to the neoplastic tissue. The boron concentration necessary

for effective BNCT has been estimated to be 15-30 µg of 10B per gram of tumor.34 These

13

10

B-containing tumor cells are then irradiated with low energy (thermal) neutrons and

undergo spontaneous fission, releasing high linear energy transfer (LET) particles, 4He2+
(α-particles) and 7Li3+ with 2.4 MeV of kinetic energy, Eq. 1.(41)

4

He2+

+

(1.78 MeV)

7

Li3+

( 1.0. MeV)

6.3%

10

B + n thermal

Eq. 1

[11B]

93.7%

4

He2+

(1.78 MeV)

+

7

Li3+

+

γ

( 1.0. MeV) (0.48 MeV)

Because of the relatively short range of destructive power of the cytotoxic LET particles
(approximately one cell diameter, 5 µm), neighboring healthy tissues are spared the
apoptotic or necrotic processes.35
Promising carboranylporphyrin candidates for BNCT will exhibit the following
characteristics: (1) high tumor cell selectivity, (2) deliver therapeutic concentrations of
10

B to tumor cells, (3) low dark cytotoxicity, (4) localize within neoplastic organelles,

preferentially within or near the cell nucleus, (5) have long retention times within
malignant tissues while being rapidly cleared from normal tissue and blood, (6) be readily
synthesized in high yield and purity, (7) be easily monitored by fluorescence microscopy
techniques.36
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1.6 A Brief History of Carboranylporphyrins
The first carboranylporphyrins were successfully synthesized by Hausholter and Rudolph
in 1978 and contained closo- or nido-carborane cages. The meso-tetracarborane clusters
were linked to the porphyrin macrocycle directly by a carbon atom, or via a methylene or
amide substituent.37 Formation of the closo-porphyrin was achieved using Rothemund
condensation reaction conditions and the porphyrin was isolated in 10 % yield. The
degraded nido-porphyrin was synthesized using a piperidine and pyridine solution in
DMF at 55oC and provided the first water-soluble carboranylporphyrin.

This first

successful synthesis of a carboranylporphyrin was intended for catalysis and not for
BNCT.
During the late 1980’s and into the mid-1990’s, other groups of researchers including
Miura, Gabel, and Kahl explored the frontiers of carboranylporphyrin syntheses. The
syntheses incorporated a BSH-moiety 1.11 which provided improved water solubility and
tumor selectivity. In 1990, Kahl et al. synthesized

a carborane-containing

protoporphyrin-IX-derived porphyrin38 1.12, BOPP, which was reported to have a
tumor/normal brain porphyrin ratio of 400:1 and a tumor/blood ratio of 11:1, 48 hours
after administration of a 100 mg/Kg body weight (b. w.) dosage in mice having a rat C6
cerebral glioma. Phase I clinical trials, however, determined that BOPP failed to deliver
therapeutic concentrations of boron to the tumors of glioblastoma patients and this
compound’s toxicity prevented higher dosage from being administered. Derivatives of
BOPP containing C=C linkages and/or nido-carboranes were synthesized and exhibited
longer retention times in tumors, less selectivity, a lower percentage of boron, and had
problems associated with formulation. VCDP 1.13 provided a water-soluble
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carboranylporphyrin which was well-tolerated at therapeutic concentrations of 270
mg/Kg b. w.. A tumor to blood ratio of 10:1 and a tumor to normal brain ratio of 6:1 was
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achieved with this compound in BALB/c mice with transplanted subcutaneous KHJJ
mammary carcinomas.39
Other early successes included the syntheses of carborane-containing mesotetraphenylporphyrins for application in BNCT. A compound containing four o-carborane
substituents 1.14, CuTCPH, delivered ~85 µg of boron/gram of tumor to mice bearing
EMT-6 tumors at a dosage of 191 mg/Kg b. w.. This is the first reported tumor ablation
(71 %) using porphyrin-mediated BNCT. The copper-containing porphyrin has particular
advantages over other metalloporphyrin-mediated BNCT: 1) Cu(II) porphyrins have short
triplet half-life so that photosensitization occurs to a minimal extent in normal tissues
exposed to light, such as skin, and 2) radioisotopes of copper are available, which allow
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imaging of the porphyrin.40, 41 Another tetra(nido-carboranyl)porphyrin derivative which
linked the carborane via an amide bond 1.15, BTPP, delivered an order of magnitude less
17

boron (12-33 µg per gram of tumor) in U-87 MG human glioma-bearing mice and was
moderately toxic.42
1.7 Recent Syntheses of Carboranylporphyrins for BNCT
The purpose of this section will be to review the recent progress in the syntheses of
carboranylporphyrins in Boron Neutron Capture Therapy (BNCT) from 2001 to the
present for comparison purposes with work described in Chapters 2, and 3. The focus
will be to examine new synthetic pathways used in the preparation of carboranylporphyrins as reported in the literature. From 2001 to the present, there has been a rapid
expansion of structurally diverse carboranylporphyrins.

New methodologies have

evolved which have met the numerous challenges posed by the syntheses of the
carboranylporphyrin macrocycle. The following examples highlight recent advances in
regioselectivity, overall yield, and total boron weight content.

•

nido-Carboranylchlorin43

Boron-containing porphyrin derivatives with long wavelength absorptions might have
application as dual sensitizers in both the BNCT and PDT of tumors because of their
ability to be activated by both light and low-energy neutrons. Recent additions to this
group of compounds are 1.17, 1.18, a closo- and nido-carboranylchlorin which were
synthesized from 1.16 according to Scheme 1-7. This scheme combines a method of
reduction at the ß-pyrrole position with functionalization, involving treatment of a 2nitro-meso-tetraarylporphyrin 1.16 with an “activated” malononitrile compound in the
presence of potassium carbonate.

A Michael addition of the anion from the active

malononitrile compound to the nitropyrrole subunit produces a nitronate anion that can be
converted, in the presence of excess anion, into a trans-chlorin. The reaction can be
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Scheme 1-7. (a) CNCH2CN, K2CO3, THF, 65oC, 7h, 41% yield; (b) Pyridine/Piperidine
(3:1), 48h, rt, resin Dowex 50WX2-100 in K+, 99% yield.
thermodynamically controlled, resulting in the formation of a fused cyclopropanochlorin,
if desired.44 Compound 1.17 displayed a strong absorption in the red region of the optical
spectrum at 642 nm. The water-soluble nido-carboranylchlorin 1.18 is non-toxic in the
dark toward human glioma T98G cells (IC50>500 M, using MTT-based assay), but is
toxic under low light doses (IC50=80 M at 0.55 J/cm2).45 The preferential sites of
subcellular localization of 1.18 were the lysosomes.
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•

β-carboranylporpyhrin46

Many of the promising compounds synthesized for BNCT have typically linked the
carborane to the meso-position of the porphyrin macrocycle. In the case of the present
Me
Me

Me

CHO

Me

a, b
NH
1.19

Me

+

NH N

Me

N HN

Me

Me
1.20
Me

Me
1.21

Scheme 1-8. (a) BF3•OEt2, CH2Cl2, rt; (b) p-chloranil, 20% yield.

compound 1.21, Scheme 1-8, the carborane groups are linked to both the meso-phenyl
rings and the β-pyrrolic positions of the porphyrin macrocycle, giving the compound 1.21
43 % boron by weight. Carboranylpyrroles containing either a direct link or a methylene
group between the carborane and pyrrole units have been previously reported47, however,
this is the first successful synthesis of a carboranylpyrrole containing a bis-methylene
linkage. Earlier attempts at the tetramerization of the pyrroles bearing carborane cages
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directly attached or with a methylene group resulted in low yields of the condensed
porphyrin due to steric and electronic effects caused by the bulky and electron-withdrawing carborane cages. Carboranylpyrrole intermediate 1.19 was condensed with the
aldehyde 1.20 using standard Lewis-acid conditions to afford the title compound 1.21 in
20 % yield.

•

Porphyrin-cobaltacarborane conjugates48

It has recently been reported that porphyrin-cobaltacarborane conjugates were prepared in
high yields via a nucleophilic ring-opening reaction of compound 1.23 with compound
1.22 as illustrated by Scheme 1-9. According to literature compound 1.23 will undergo a
a dioxane ring-opening reaction in the presence of a variety of nucleophilic reagents
including halogens, hydroxide anions, amines, cyanide, imides, pyrrolic salts, and
phenolate.49-52 The product 1.24 contains eight dicarbollide cages per porphyrin linked via
ethylene glycol chains and may have great promise for BNCT due to the stability of the
cobaltbis(dicarbollide) anion [Co(C2B9H11)2]- towards acids, moderate bases, high
temperature, and radiation.53 The use of polyethylene glycol (PEG) linkages also has the
added benefit of improving overall water solubility and thus preventing aggregation of
the macrocycle. Recent cellular studies have found cobaltacarborane conjugates to
localize subcellularly within the cell lysosomes and vesicles and that uptake in human
HEp2 cells was dependant on the number of cobaltacarborane cages. A cobaltacarborane
conjugate containing sixteen carborane clusters per macrocycle has been synthesized.54
Additionally, a cobaltacarborane linked to a HIV-1 Tat 48-60 peptide sequence has been
synthesized and has proven to have enhanced cellular uptake in HEp2 cells due to the cell
penetrating properties of the peptide linkage.55
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Scheme 1-9. (a) CsCo3, acetone; (b) Sephadex LH-20, MeOH

•

Meso-tetra[(nido-carboranylmethyl)phenyl]porphyrins35

Two free-base 1.25, 1.27 and two Zn-metalated nido-carboranylporphyrins (para- and
meta-regioisomers) 1.26, 1.28 were synthesized in fair overall yields (16 and 18%,
respectively) via the Lindsey method according to Scheme 1-10.

In vitro cell toxicity,

uptake/efflux, and subcellular localization studies using rat 9L, mouse B16 and/or human
U-373MG cells indicated that these porphyrins display very low dark cytotoxicities (IC50
values higher than 150 µM in all cell lines) and time and concentration-dependent uptake
by cells. Although no apparent differences were observed between the in vitro properties
of the para- and the meta-substituted porphyrins, the location of the carborane cage has a
significant effect on their conformation and aggregation behavior. It is suggested that the
low cellular uptake of these porphyrins is associated with an as yet unidentified plasma
component(s) that inhibit binding and uptake.
compounds was 26-32%.

Boron by weight delivery of these

Intracellular localization using confocal fluorescence

microscopy indicated the punctuate fluorescence was predominantly perinuclear, with
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Scheme 1-10 (a) pyrrole, TFA, CH2Cl2; (b) p-chloranil 32% yield; (c) ZnCl2 in
CH2Cl2/THF/pyridine (d) pyridine/piperidine (3:1), 36 h; (e) resin Dowex 50WX2-100 in
K+, 94% yield.

many cells having an additional local area of concentration that appeared to be adjacent
to the nuclear membrane. Preliminary co-localization experiments using organellespecific fluorescent probes indicate that porphyrin 1.27 localizes preferentially in the cell
lysosomes.
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Me

•

5, 15-Di[3, 5-(nido-carboranylmethyl)phenyl]porphyrins56

The title compounds 1.34 and 1.35 were synthesized in approximately 13% overall yield
from a commercially available starting material as outlined in Scheme 1-11. The ninestep total synthesis incorporates a MacDonald [2 +2] condensation of dicarboranylbenzaldehyde 1.30 with an unsubstituted dipyrromethane 1.31 to afford porphyrin 1.32.
The closo-porphyrin was subsequently either metalated and degraded to the nido-form, or
the free base was degraded to its corresponding nido-form using standard methods.
The biodistribution of nido-carboranylporphyrins 1.34 and 1.35 in BALB/c mice
bearing EMT-6 mammary tumors indicated both compounds were effective tumor
localizers and delivered therapeutic concentrations of boron to tumors. The measured
concentration of boron/gram of tumor two days after injections for 1.34 and 1.35 was
32.5± 7.1 and 54.3 ±14 µg/g, respectively. A total boron dose of 23 mg/Kg body weight
was reported.

In a comparison of metalated versus free-base porphyrin, the Zn(II)

complex 1.35 was found to deliver 1.2-1.7 times higher amounts of boron to tumors than
1.34. Two days after injections the tumor-to-blood boron concentration ratio was 4.7:1
and 9.8:1 for 1.34 and 1.35, respectively. Tumor-to-brain concentration ratios of >100/1
for both porphyrins was reported. The eleven-step synthesis of the title compound was
accomplished using commercially available starting materials and proceeded in
approximately

15%

overall

yield

as

outlined

in

Scheme

1-11.

The

dicarboranylbenzaldehyde 1.30 is a common intermediate in porphyrin condensations,
allowing in this instance for tetramerization with freshly distilled pyrrole using Lindsey’s
conditions. The closo-porphyrin product 1.36 was subsequently either metalated 1.37 and
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degraded to the nido-form 1.39, or the free base 1.36 was degraded to its corresponding
nido-form 1.38 using standard methods.
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Scheme 1-11. (a) 1-lithium-2-methyl-o-carborane, THF, LiI, rt, 16 h, 63% yield; (b) nBuLi, THF, -78oC for 30 min; (c) DMF, -78oC for 30 min then 0oC for 1 h; (d) 5%
aqueous HCl, rt for 15 min, 71% yield from 1.29; (e) TFA, CH2Cl2, rt overnight; (f) pchloranil, rt for 6h, 34% yield from 1.30; (g) ZnCl2, CH2Cl2/THF (1/10), pyridine, 89%
yield; (h) pyridine/piperidine (3:1), 3h; (i) resin Dowex 50WX2-100 in K+, 93-95% yield
from 1.32 and 1.33. A modified synthetic route to porphyrin 1.32 was developed as part
of this dissertation and is detailed extensively in Chapter 3.

•

5, 10, 15, 20-tetra[3, 5-(nido-carboranylmethyl)phenyl]porphyrin57

Porphyrin 1.39 was observed to have low dark toxicity toward V79 hamster fibroblast
cells using a clonogenic assay (CS50≥250 µM). Carboranylporphyrins bearing up to four
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carborane cages 1.28 have been previously reported in this chapter56 to have low dark
toxicity, but compound 1.39 is the first reported instance of a porphyrin bearing eight
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Scheme 1-12. (a) pyrrole, TFA, CH2Cl2, rt overnight; (b) p-chloranil, rt for 6h, 15%
yield; (c) ZnCl2, CH2Cl2/THF (1/10), pyridine, 50% yield; (d) pyridine/piperidine (3:1),
72h; (e) resin Dowex 50WX2-100 in Na+, quant. yield; (f) TFA, H2SO4, 30 min, rt, 96%
yield.

nido-carborane groups linked to the porphyrin macrocycle having similarly low dark
cytotoxicity as shown in Scheme 1-12. However, the more hydrophilic octa-anionic
porphyrin 1.39 was found to accumulate within human glioblastoma T98G cells to a
significantly lower extent than tetra-anionic porphyrin 1.28 (para-substituted). Studies in
T98G cells indicated the cell lysosomes as the intracellular site of localization for
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compound 1.39. This was confirmed by a co-localization experiment of the lysosomespecific probe lysoSensor. T98G cellular uptake experiments concluded that the cellular
uptake of 1.39 was concentration and time-dependent.

•

Carboranyl-tetrabenzoporphyrin58

The seven-step synthesis of the title compound, TBP 1.43, is illustrated in Scheme 1-13.
Condensation-cyclization of butanopyrrole 1.40 and carboranyl-benzaldehyde 1.41
proceeded under Lindsey-type conditions and yielded the carboranylporphyrin product
which was metalated using CuCl2. A second oxidation using DDQ yielded the unique
tetrabezoporphyrin 1.42 which subsequently was demetalated, degraded, and subject to
CHO
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Scheme 1-13. (a) BF3•OEt2, CH2Cl2, rt, 1h; (b) DDQ (2 equiv.), CH2Cl2, reflux, 1h,
60% yield from 1.41; (c) CuCl2, toluene, reflux, 4h, quant. yield; (d) DDQ (8 equiv.),
toluene, reflux, 10 min, 75% yield; (e) conc. H2SO4, 5 min, quant. yield; (f) Bu4NF, THF,
reflux, 12h; (g) resin Dowex 50WX2-100 in Na+ form, 90% yield from 1.42.
ion exchange to provide TBP.
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The dark toxicity of TBP was evaluated in V79 hamster fibroblast cells using an
MTT-based cell viability assay. Concentrations up to 300 µM showed no effect on cell
viability after an incubation period of 24 h.

These results are in agreement with

previously reported results.35However, TBP showed a significantly higher uptake in
human glioblastoma T98G cells in vitro than previously reported compounds, probably
due to the increased hydrophobicity of its four ß,ß'-porphyrin fused benzene rings.
Animal toxicity studies using male and female BALB/c mice determined that a maximum
intraperitoneal dosage of 160 mg/kg could be administered without causing a toxic
response.59 These results suggest that TBP is a promising compound for PDT and BNCT
therapies.
1.9 Conclusion
Porphyrin-based compounds constitute an important class of tumor-localizing agents for
applications in BNCT and PDT. Porphyrins bearing boron clusters can be obtained by
total synthesis from boronated precursors (pyrroles or aldehydes) or by direct
functionalization of commercially available porphyrin macrocycles. While the former
approach is preferred for the preparation of symmetrically-substituted compounds, the
latter is generally used for the synthesis of asymmetric porphyrin derivatives.
Several porphyrins with unique properties have been successfully synthesized and tested
in vitro and offer promise as therapeutic treatments for a variety of diseases. Many others
need to be further tested in animal studies to realize their full promise. Given the
pressing need to develop still better treatments, additional funding for further research is
imperative.
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What follows in Chapter 2 is a summary of the efforts to successfully synthesize
additional compounds for potential applications in PDT and BNCT. The final chapter
describes efforts to streamline the syntheses of carboranylporphyrin derivatives using as
few steps as possible with minimal or no purification and with highest yield.
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Chapter 2
Syntheses of Trimethylamine- and Phosphonate-substituted Carboranylporphyrins
for Application in BNCT
2.1 Introduction
One of the many challenges facing a research chemist attempting the syntheses of
carboranylporphyrins is to design compounds which are amphiphilic, possessing both
hydrophilic and lipophilic character.1, 2 Hydrophilicity is necessary because BNCT and
PDT require the intravenous injection of therapeutic concentrations of compound into the
blood stream; thus, the compound must be water-soluble. Lipophilicity is necessary for
transfer across the cellular membrane and into cellular organelles where the compound
can be excited to its cytotoxic state. If a compound is too hydrophilic, it will not cross the
cellular membrane. If it is too lipophilic, the compound will have formulation problems
and not enter the blood stream.

What is required is a delicate balance between

hydrophilicity and lipophilicity.
Herein is reported the syntheses of new amphiphilic closo-carboranylporphyrins (2.5d,
2.6c, 2.6d, 2.7c, 2.7d and 2.8d) bearing either positively charged quaternary ammonium
or negatively charged phosphonate water-solubilizing groups, and two to six closocarborane cages. Only a few water-soluble closo-carboranylporphyrins have been
previously reported in the literature, bearing carboxylates or a PEG as water-solubilizing
groups.3 These new closo-carboranylporphyrins contain either phosphonate groups that
can form multiple hydrogen bonds with biological molecules, or quaternary ammonium
salts that can potentially target highly vulnerable intracellular sites, such as the nuclei,
and induce effective DNA and RNA damage.4-7 The X-ray molecular structures of four
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key intermediates (2.1, 2.2, 2.3 and 2.4a) and of two target porphyrins (2.5b and 2.6c) are
discussed.
2.2 Results
2.2.1 Porphyrin Syntheses
Porphyrins 2.5-2.8 containing two to six carborane cages (18-38% boron by weight) were
synthesized via a [2+2] condensation of dicarboranyl-benzaldehyde 2.3 with an amino- or
phosphonate-substituted dipyrromethane 2.4a,b, as shown in Scheme 2-1. Due to acidcatalyzed scrambling in these reactions porphyrins 2.5-2.8 were obtained in a single-pot
reaction and isolated in 2-8% yield, along with 2-9% of the corresponding octacarboranylporphyrin (H2OCP)1, and <1% of other minor porphyrin products. The
benzonitrile 2.1, prepared according to the procedure of Bodwell et al.8, reacted with insitu prepared 1-lithium-2-methyl-o-carborane producing the dicarboranyl-benzonitrile 2.2
in 51% yield. The cyano group of compound 2.2 was reduced to formyl using DIBAL-H,
giving benzaldehyde 2.3 in 62% yield. Vicente et al. have previously reported a related
synthesis of dicarboranyl-benzaldehyde 2.39 from 3,5-dimethylbromobenzene in 15%
overall yield.
The new synthesis of 2.3 relies on the readily reduction of the cyano group of 2.2, as
previously reported for other benzonitriles,10 rather than on a lithium/bromide exchange
followed by DMF addition and acidic hydrolysis,9 thus involving less steps.
Dipyrromethanes 2.4 were prepared from the reaction of the corresponding benzaldehyde
with an excess of pyrrole using TFA as the catalyst, in 70-86% yields, as previously
reported.11-13 The condensation of compounds 2.3 and 2.4a via a [2+2] methodology,11, 14
using BF3•OEt2 for 1 h at room temperature, followed by oxidation under mild conditions
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with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) gave porphyrins 2.6a, 2.7a and
H2OCP in 2.1, 6.3 and 8.5% yields, respectively, as major products. On the other hand,
the condensation of 2.3 and 2.4b under similar conditions but using BF3•OEt2 for only 4
min, afforded porphyrins 2.6b, 2.7b, 2.8b and H2OCP in 2.6, 8.0, 4.5 and 2.1% yields,
respectively. Other porphyrins were also obtained as minor products (< 1% yield) as a
result of the scrambling but were not isolated in sufficient amounts for characterization.
In order to achieve water solubility, the phosphonate esters were cleaved to the
corresponding phosphonic acids using bromotrimethylsilane followed by hydrolysis15 in
78-99% yield, and the dimethylamino groups were quaternized with excess iodomethane
in dichloromethane,5 in 83-92% yield. While the porphyrins containing either the diester
phosphonate or dimethylamino functionalities are highly soluble in dichloromethane, the
phosphonic acid-containing porphyrins are only soluble in DMSO and partially soluble in
water, and the trimethylammonium-porphyrins are soluble in polar solvents (such as
acetone and methanol) and also partially water-soluble. Porphyrin 2.5d exhibited
particularly low solubility in all solvents, including DMSO.
2.2.2 Molecular Structures
Crystals of intermediate dibromobenzonitrile 2.1 were grown from ethyl acetate/hexane,
and

those

of

carboranyl-benzonitrile

2.2,

carboranyl-benzaldehyde

2.3,

and

dipyrromethane 2.4a were grown from CHCl3/hexane. Their molecular structures are
shown in Figures 2-1, 2-2, 2-3 and 2-4, respectively, confirming their identities. Crystals
of the toluene solvate of porphyrin 2.5b were grown from CHCl3/toluene, and those of
the chloroform solvate of 2.6a were obtained by slow evaporation of a chloroform
solution over a period of several days. The X-ray structures of porphyrins 2.5b and 2.6a
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Scheme 2-1: (i) 1-Lithium-2-methyl-o-carborane, THF, LiI, rt, 20 h (51%); (ii) DIBAL,
toluene followed by 10% H2SO4 (62%); (iii) pyrrole, TFA, CH2Cl2, rt (70-86%); (iv)
BF3•OEt2, CH2Cl2, rt, 4 min – 1 h; (v) DDQ, rt for 30 min (overall 17-22%).
are shown in Figures 2-5 and 2-6, respectively. In the crystal, porphyrin 2.5b lies on an
inversion center, so the four N atoms are symmetry-required to be rigorously coplanar.
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The entire porphyrin ring deviates little from coplanarity, exhibiting a mean deviation of
0.029 Å for the 24-atom core and maximum deviation of 0.067(4) Å. The phenyl rings
carrying the phosphonates form dihedral angles of 70.9(1)˚ with the porphyrin plane, and
the phenyl rings carrying the carboranes form dihedral angles of 67.0(1)˚ with it. In
porphyrin 2.6a, the four porphyrin N atoms in Figure 2-6 are coplanar to within 0.02(2)
Å, but the 24-atom porphyrin core deviates somewhat from planarity, its atoms exhibiting
a mean deviation of 0.12 Å from their best plane, with maximum deviation 0.26(3) Å.
The distortion is mostly a twist about an axis bisecting the pyrrole between the two
Me2NPh groups and the pyrrole between the two carborane-substituted phenyl groups.
This twist places the two NMe2 nitrogen atoms 1.54(4) and -0.70(3) Å above and below
the porphyrin best plane, as illustrated in Figure 2-6a, a view down the twist axis. The
phenyl rings form dihedral angles which fall in the range 71.3(6) - 82.3(6)˚ with the
porphyrin best plane.
2.3 Discussion
The new series of amphiphilic, closo-carboranylporphyrins 2.5-2.8 was prepared in a
single reaction using a MacDonald-type [2+2] condensation16 of either dimethylamino- or
diethylphosphonate-dipyrromethane with dicarboranyl-benzaldehyde 2.3 (Scheme 2-1).
Various reaction conditions were investigated that led to the highest yields of the target
porphyrins 2.5-2.8, bearing one to three water-solubilizing groups and two to six closocarborane cages, including different starting reagents, acid catalysts, reagent
concentrations, solvents, and reaction times.11,

14

(Sections 2.6.1 - 2.6.3). The optimal

conditions involved the use of 10 mM dipyrromethane and benzaldehyde concentrations
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Figure 2-1. The molecular structure of 2.1 as determined by X-ray crystallography, with
ellipsoids at the 50% level.

Figure 2-2. The molecular structure of 2.2 with 50% ellipsoids. H-atoms are not shown.
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Figure 2-3. The molecular structure of 2.3 with 50% ellipsoids. H-atoms are not shown.

Figure 2-4. The molecular structure of 2.4a with 50% ellipsoids.
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Figure 2-5. The molecular structure of 2.5b with 20% ellipsoids. Solvent molecules and
H-atoms are not shown.
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a

b

Figure 2-6. The molecular structure of porphyrin 2.6a with 20% spheres. (a) top view;
(b) side view. Solvent molecules and H-atoms are not shown.
in dichloromethane and 2 equiv. of BF3•OEt2 for either 1 h (in the case of 2.4a + 2.3) or 4
min (for 2.4b + 2.3). The use of dipyrromethanes 2.4 in a [2+2] condensation rather than
a mixed aldehyde condensation afforded higher yields of the target porphyrins containing
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at least one dipyrromethane motif, by minimizing the formation of H2OCP, which was
always a side product in these reactions. When 5-(4-acetamidophenyl)dipyrromethane
2.15 (Scheme 2-4) was used in place of 2.4a, lower yields of the targeted porphyrins were
obtained due to the additional step required to cleave the acetamido group (ethanol/HCl
at reflux for 24 h) and the isolation of a tetracarboranylcorrole as one of the main
products. The condensation of 5-[bis(3,5-(2-methyl-o-carboran-1-yl)methyl)phenyl]dipyrromethane 2.12 (Scheme 2-2) with bromo-, phosphonate-, or amino-substituted
benzaldehydes also gave lower yields of the targeted porphyrins; in fact, no carboranecontaining phosphonate-substituted porphyrins were obtained using this methodology.
The acid-catalyzed scrambling was more significant in the [2+2] condensation of 2.4a
with 2.3 probably as a result of the strong electron-donating effect of the dimethylamino
group and the longer reaction time necessary to drive the reaction to completion; in this
case the trans-porphyrin 2.5a was not among the major products of the reaction and
H2OCP was the main product obtained in 8.5% yield. Under the above optimal conditions
for the condensation of 2.4b and 2.3, porphyrin 2.7b bearing a single phosphonate ester
was the major product obtained, followed by 2.8b and 2.6b; in this case H2OCP was only
obtained in 2.1% yield. Although acid-catalyzed scrambling reactions are generally
avoided in order to minimize challenging chromatographic separations, this methodology
allowed the isolation and characterization of reasonable amounts of several interesting
porphyrin targets.
All new compounds were characterized by spectroscopic techniques (MS, 1H NMR,
UV-Vis) and in addition, benzonitriles 2.1 and 2.2, benzaldehyde 2.3, dipyrromethane
2.4a and porphyrins 2.5b and 2.6a were also characterized by X-ray crystallography. It is
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interesting to note that while the porphyrin ring in porphyrin 2.5b, bearing two
phosphonic esters on opposite p-phenyl positions is essentially flat, that of porphyrin 2.6a
with two adjacent p-dimethylaminophenyl groups is moderately distorted from planarity,
showing a twisted conformation. Such porphyrin distortions from planarity have been
previously observed17 and seem to be associated with the electronic interactions between
the water-soluble groups rather than with the 3,5-dicarboranylmethylphenyl groups.1,

9

Upon quaternization of the dimethylamino groups of 2.6a, i.e. in 2.6c, a more
pronounced distortion of the porphyrin is expected, as has previously been observed for a
5,10-di(4-trimethylamino)phenyl-15,20-diphenylporphyrin.5
As a consequence of the highly hydrophobic character of the closo-carborane cages,
porphyrins 2.5b, 2.6a,b, 2.7a,b and 2.8b were completely insoluble in water. Two
strategies

are

usually

employed

for

conferring

partial

water-solubility

to

carboranylporphyrins,3 (1) the introduction of water-solubilizing groups (such as amino,
hydroxyl or carboxylate), or (2) the deboronation of o-carborane cages to the
corresponding anionic nido-carboranes. In the present study a new series of closocarboranylporphyrins bearing either positively charged quaternary ammonium or
negatively charged phosphonate water-solubilizing groups were synthesized and
characterized which could potentially interact with DNA18,

19

and the phosphonate-

substituted porphyrins could form multiple hydrogen bonds with biological substrates.
Interestingly, porphyrin 2.5d bearing two phosphonic acid substituents on opposite pphenyl positions showed very limited water-solubility, probably as a result of the
formation of large aggregates and their subsequent precipitation in aqueous media.20
Porphyrins 2.5d, 2.6c, 2.6d, 2.7c, 2.7d and 2.8d showed similar absorption and emission
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spectra in DMSO, typical for meso-tetraphenylporphyrins, as shown in Figure 2-7.
However, in HEPES buffer (20 mM, pH 7.4) containing 1% DMSO all porphyrins show
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Figure 2-7. (a-f) Fluorescence emission spectra of porphyrins 2.5d, 2.6c, 2.6d, 2.7c,
2.7d, and 2.8d at 1 x 10-6 M in a) DMSO (solid line), and b) freshly prepared HEPES
buffer (20 mM, pH 7.4) containing 1% DMSO (dashed line). Excitation at 420 nm.
significant broadening of their emission bands and fluorescence quenching, indicating
aggregation (see Figure 2-7) as has been previously observed.21 Interestingly, porphyrins
2.5d, 2.6c, 2.7c and 2.7d displayed red-shifted (1-4 nm) emission bands while porphyrins
2.6d and 2.8d showed blue-shifted (3-5 nm) bands, suggesting the formation of different
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types of aggregates. At physiologic pH the phosphonic acid groups mainly exist in their
mono-anionic form (i.e. as PO3H¯) and the resulting anionic porphyrins can aggregate as
a result of both p-p interactions and hydrogen bond formation. It has been recently shown
that negatively charged cobaltacarborane-porphyrins containing up to eight negative
charges form large aggregates in aqueous solutions.21, 22
2.4 Conclusions
The syntheses of six new amphiphilic closo-carboranylporphyrins bearing either
positively charged quaternary ammonium (2.6c, 2.7c) or negatively charged phosphonate
(2.5d, 2.6d, 2.7d and 2.8d) groups is reported. These compounds may have promising
potential for BNCT due to their ability to either intercalate with DNA or form multiple
hydrogen bonds with biological molecules. The X-ray molecular structures of four
intermediates (2.1, 2.2, 2.3 and 2.4a) and of two target porphyrins (2.5b and 2.6c) are
discussed. In vitro cell studies using HEp2 and T98G assays have been performed by Mr.
Tim Jensen at Louisiana State University in Baton Rouge, Louisiana on five of the six
compounds presented in this chapter and the results are presented in Chapter 4 of this
dissertation.23
2.5. Experimental
2.5.1. General
All reactions were carried out under an argon atmosphere in dried solvents.
Commercially available starting compounds were purchased from Sigma-Aldrich or from
Katchem, Ltd. and used directly without further purification. Silica gel 60 (70-230 mesh,
Merck) was used for column chromatography. Analytical thin-layer chromatography
(TLC) was performed using Merck 60 F254 silica gel (precoated sheets, 0.2 mm thick).
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1

H-NMR spectra were obtained using a Bruker DPX 300 MHz spectrometer; chemical

shifts are expressed in ppm relative to TMS (0 ppm). Electronic absorption spectra were
measured on a Perkin Elmer Lambda 35 UV-Vis spectrophotometer. Low-resolution
mass spectra (MS) were obtained on a Bruker Proflex III MALDI-TOF mass
spectrometer. High-resolution mass spectra (HRMS) were obtained using ESI-TOF under
negative mode on an Agilent Technologies Time-of-Flight LC/MS 6210; the isotope
peaks were matched with calculated isotope patterns (see Supplementary data) and only
the most abundant peaks are listed below for each porphyrin. Melting points were
measured on a MEL-TEMP apparatus.

•

Bis(3,5-bromomethyl)benzonitrile (2.1)8: To a round-bottomed flask containing

dichloromethane (460 mL) was added 3,5-dimethylbenzonitrile (5.00 g, 38 mmol), NBS
(15.00 g, 84 mmol), and benzoyl peroxide (0.048 g, 0.20 mmol). The reaction mixture
was heated to reflux while stirring under argon. Upon reaching reflux a white floodlight
was positioned within four inches of the reaction vessel. After 1 h the reaction mixture
was cooled to room temperature and 50 mL of distilled water was added to quench

Figure 2-8: 1H-NMR spectrum of 3,5-bis-bromomethyl-benzonitrile 2.1 in CH2Cl2 at
300 MHz
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the reaction. The organic phase was washed once with water, once with brine, and then
dried over Na2SO4, and the solvent removed under vacuum to yield a yellow/orange
residue. The crude residue was dried onto silica and purified by silica column
chromatography using ethyl acetate/hexane 1:4 for elution. The pure product was
collected affording 4.47 g of the title compound as a white solid in 40 % yield. m. p. =
114-115 oC; MS (GC) m/z 289.8 [M+1]; 1H NMR (CDCl3) δ ppm: 4.50 (s, 4H, CH2),
7.65 (s, 2H, o-ArH), 7.68 (s, 1H, p-ArH) as shown in Figure 2-8.

•

Bis[3,5-(2-methyl-o-carboran-1-yl)methyl]benzonitrile (2.2): n-Butyllithium

(23.63 mL, 1.6 M in hexane) was added drop wise to a solution of 1-methyl-o-carborane
(4.76 g, 30 mmol) in dry THF (450 mL) at a temperature between –5 and 0 oC, under
argon. The mixture was stirred at this temperature for 1.5 h, and then compound 2.1 (4.37
g, 15.10 mmol) and LiI (0.628 g, 4.69 mmol) in THF (50 mL) were added. The final
reaction mixture was allowed to warm to room temperature and after 20 h the reaction
was quenched with water and the solvent removed under vacuum. The crude residue was
dissolved in ethyl acetate and washed once with water, once with brine, dried over
Na2SO4, and the solvent removed under vacuum. The yellow residue was dried onto
silica and purified by silica column chromatography using ethyl acetate/hexane 1:4 for
elution. The pure title compound was obtained as an off-white solid (2.70 g) in 51% yield
(40 % conversion). Recovered 1.05 g of 1-methyl-o-carborane. m. p. = 235-237 oC; MS
(ESI) m/z 443.24; 1H NMR (CDCl3) δ ppm 1.4–3.0 (br, 20H, BH), 2.22 (s, 6H, CH3),
3.58 (s, 4H, CH2), 7.36 (s, 1H, p-ArH), 7.56 (s, 2H, o-ArH).

•

Bis[3,5-(2-methyl-o-carboran-1-yl)methyl]benzaldehyde (2.3): A solution of

compound 2.2 (11.14 g, 25.14 mmol) in dry toluene (500 mL) was flushed with argon for
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10 min. The reaction vessel was then cooled to 0 oC and DIBAL-H (1.5 M in toluene)
(36.87 mL, 55.3 mmol) was slowly added drop wise while stirring under argon. The
reaction was heated to 60-65 oC for 39 h, then cooled to 0 oC and a cold 10 % H2SO4
aqueous solution (228 mL) was slowly added to avoid foaming. Toluene (800 mL) was

Figure 2-9: 1H-NMR spectrum of bis [3,5-(1-methyl-o-carboranyl)methyl] benzaldehyde
2.3 in CDCl3 at 300 MHz
added and the reaction mixture was stirred for an additional 62 h under argon. The
organic phase was washed once with Na2HCO3, once with water, once with brine, dried
over Na2SO4 and the solvent removed under vacuum to yield a crude white solid. This
solid was dissolved in dichloromethane, dried onto silica and purified by silica column
chromatography using 1:1 hexane/dichloromethane for elution. Pure title compound was
obtained as a white solid (7.07 g) in 62 % yield. The spectroscopic data for the title
compound is in full agreement with that reported in the literature as shown in Figure 29.1, 9 The crystalline form of compound 2.3 appears in Figure 2-10.
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Figure 2-10: Photograph of bis[3,5-(1-methyl-o-carboranyl)methyl]benzaldehyde 2.3
crystal.
•

5-(4-Dimethylamino)phenyldipyrromethane (2.4a) was prepared as described

in the literature and its spectroscopic data are in full agreement with that previously
reported.11 The X-ray structure of 2.4a appears in Figure 2-4.

•

5-(4-Phosphonate diethylester)phenyldipyrromethane (2.4b): A solution of

compound 2.3 (0.047 g, 0.20 mmol) and freshly distilled pyrrole (0.80 mL, 11.5 mmol)
was purged with nitrogen for 5 min. TFA (2 µL, 0.023 mmol) was added and the final
solution was stirred at room temperature in a sealed reaction vessel for 20 min. The light
green crude material was dried onto silica and purified by silica column chromatography
using methanol/dichloromethane 1:33. The title compound was obtained (65 mg) in 86 %
yield, as a yellow residue. 1H NMR (CDCl3) δ ppm: 1.36 (t, 6H, CH3, J = 7.0 Hz), 4.10
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(m, 4H, CH2), 5.60 (s, 1H, CH), 6.01 (s, 2H, o-ArH), 6.18 (s, 2H, m-ArH), 6.78 (s, 2H, αH), 7.35 (m, 2H, β-H), 7.62 (m, 2H, β-H), 9.56 (br, 2H, NH) as shown in Figure 2-11.

Figure 2-11: 1H-NMR spectrum of 5-(4-phosphonic acid diethyl ester)
phenyldipyrromethane 2.4b in CD2Cl2 at 300 MHz
2.5.1.1 General Procedure for Porphyrin Synthesis: A solution of dipyrromethane 2.4
(1.12 mmol) and bis[3,5-(2-methyl-o-carboran-1-yl)methyl]benzaldehyde 2.3 (0.498 g,
1.12 mmol) in 112 mL of dichloromethane was purged with argon for 15 min. BF3•OEt2
(0.283 mL, 2.23 mmol) was added and the reaction was stirred in a sealed reaction vessel.
After 1 h (for 2.4a) or 4 min (for 2.4b) DDQ (0.336 g, 1.48 mmol) and Et3N (0.31 mL,
2.23 mmol) were added and the reaction mixture stirred for 30 min. The mixture was then
dried onto silica and filtered through a plug of silica gel using dichloromethane/hexane
2:1 for elution. The crude mixture was further purified using preparative silica TLC
plates and dichloromethane/hexane 3:1 for elution to yield the porphyrins.
2.5.1.2 Deprotection: The diethyl ester porphyrins were dissolved in dichloromethane
and purged with argon for 5 min. The reaction vessel was then sealed and
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bromotrimethylsilane was added by microliter syringe (16 equiv/phosphonate diester)
while stirring at room temperature. The final mixture was stirred for 24 h. All solvents
were removed under vacuum and the crude green residue was dissolved in a 1:4
H2O/THF solution and allowed to stir for 2 h. The organic solvent was removed under
vacuum and the deprotected porphyrins were filtered and washed repeatedly with
distilled water.
2.5.1.3 Quaternization: The dimethylamino porphyrins were dissolved in a 2:5 solution
of CH2Cl2/CH3I and the resulting mixture allowed to stand without stirring in a sealed
reaction vessel for 72 h at room temperature. The quaternized products precipitated out of
solution and were filtered and washed repeatedly with dichloromethane. Porphyrins 2.6c
and 2.7c were partially demethylated upon standing over a period of one week (for 2.6c)
or one month (for 2.7c), thus reforming the starting porphyrins 2.6a and 2.7a,
respectively.
5,15-Bis-(4-phosphonate diethyl ester)-10,20-bis[(3,5-(2-methyl-o-carboran-1yl) methylphenyl]porphyrin (2.5b):

•

This porphyrin was obtained (31 mg, 3.6% yield) as a purple/red solid. m.p.: > 300 oC;
MS (MALDI) m/z 1552.78 [M-CH3]+; 1H NMR (CD2Cl2) δ ppm: -2.80 (br, 2H, NH),
1.60 (t, 12H, CH3, J = 7.0 Hz), 1.3 – 3.4 (br, 40H, BH), 2.27 (s, 12H, CH3), 3.85 (s, 8H,
CH2), 4.40 (m, 8H, CH2), 7.58 (s, 2H, ArH), 8.12 (s, 4H, ArH), 8.26 (m, 4H, ArH), 8.40
(m, 4H, ArH), 8.95 (m, 8H, β-H) as shown in Figure 2-12. UV-Vis (CH2Cl2) λmax: 419
nm (ε 331,000), 514 (15,400), 548 (6,000), 588 (4,800), 643 (2,800). The crystalline form
of 2.5b is shown in Figure 2-13. Deprotection afforded the corresponding phosphonic
acid porphyrin (2.5d) in 83% yield as a green solid. m.p.: > 300 oC; HRMS (ESI) m/z
1457.0262 [M+H]+, calculated for C60H88B40N4O6P2 1456.0195; 1H NMR (DMSO-d6) δ
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ppm: -2.92 (br, 2H, NH), 2.21 (s, 12H, CH3), 1.3 – 3.4 (br, 40H, BH), 3.92 (s, 8H, CH2),
7.63 (s, 2H, ArH), 8.15 (br, 8H, ArH), 8.29 (br, 4H, ArH), 8.85 (br, 8H, β-H). UV-Vis
(DMSO) λmax: 420 nm (ε 379,800), 515 (18,300), 550 (9,100), 589 (6,300), 645 (5,300).
HRMS of 2.5d is shown in Figure 2-14.

Figure 2-12: 5,15-bis-(4-phosphonic acid diethylester)-10,20-bis[(3,5-(1-methyl-ocarboranylmethyl)phenyl]porphyrin 2.5b in CD2Cl2 at 300 MHz

Figure 2-13 False-color photograph of porphyrin 2.5b crystal
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Figure 2-14: HRMS of phosphonic acid porphyrin 2.5d

•
5,10-Bis-(4-dimethylaminophenyl)-15,20-bis[3,5-(2-methyl-o-carboran-1-yl)methylphenyl] porphyrin (2.6a):
This porphyrin was obtained in 2.1% yield as a black solid. M.p.: > 300 oC, MS
(MALDI) m/z 1380.90 [M+]; 1H NMR (CD2Cl2) δ ppm: -2.69 (s, 2H, NH), 1.25-3.1 (br,
40H, BH), 2.24 (s, 12H, CH3), 3.25 (s, 12H, CH3), 3.79 (s, 8H, CH2), 7.17 (br, 4H, ArH),
7.51 (s, 2H, ArH), 8.07-8.12 (m, 8H, ArH), 8.85 (br, 4H, β-H), 8.99 (s, 2H, β-H), 9.03
(br, 2H, β-H). UV-Vis (DMSO) λmax: 423 nm (ε 171,000), 523 (13,500), 568 (14,200),
595 (8,500), 657 (7,300). Quaternization of this porphyrin afforded the corresponding
quaternary ammonium iodide salt (2.6c) in 83% yield as a purple/red solid. M.p.: > 300
o

C, HRMS (ESI) m/z 706.1089 [M – 2I]2+, calculated for C66H102B40N6 706.1090; 1H

NMR (acetone-d6) δ ppm: -2.79 (s, 2H, NH), 1.25-3.1 (br, 40H, BH), 2.37 (s, 12H, CH3),
4.07 (s, 8H, CH2), 4.29 (s, 18H, CH3), 7.86 (s, 2H, p-ArH), 8.22 (s, 4H, ArH), 8.55 (br,
4H, ArH), 8.65 (br, 4H, ArH), 8.88-8.99 (m, 8H, β-H). UV-Vis (DMSO) λmax: 419 nm (ε
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406,100), 514 (11,800), 548 (6,300), 588 (4,500), 644 (3,200). HRMS of 2.6c is shown in
Figure 2-15.

Figure 2-15: HRMS of phosphonic acid porphyrin 2.6c

5,10-Bis-(4-phosphonate diethylester)-15,20-bis[(3,5-(2-methyl-o-carboran-1yl) methylphenyl]porphyrin (2.6b)

•

This porphyrin was obtained in 2.6% yield as a purple solid. M.p. 282.8 oC; MS
(MALDI) m/z 1552.78 [M-CH3]+; 1H NMR (CD2Cl2) δ ppm: -2.83 (br, 2H, NH), 1.55 (t,
12H, CH3, J = 7.0 Hz), 1.3 – 3.4 (br, 40H, BH), 2.27 (s, 12H, CH3), 3.85 (s, 8H, CH2),
4.39 (m, 8H, CH2), 7.58 (s, 2H, ArH), 8.13 (s, 4H, ArH), 8.25 (m, 4H, ArH), 8.41 (m,
4H, ArH), 8.97 (m, 8H, β-H) as shown in Figure 2-16. UV-Vis (CH2Cl2) λmax: 419 nm
(ε 352,900), 514 (18,000), 549 (6,800), 589 (5,500), 643 (3,400). Deprotection afforded
the corresponding phosphonic acid porphyrin (2.6d) in 78% yield as a green solid. M.p.
>300 oC; HRMS (ESI) m/z 1457.0260 [M + H]+, calculated for C60H88B40N4O6P2
1456.0195; 1H NMR (d-DMSO) δ ppm: -2.92 (br, 2H, NH), 1.3 – 3.4 (br, 40H, BH), 2.27
(s, 12H, CH3), 3.97 (s, 8H, CH2), 7.72 (s, 2H, ArH), 8.08-8.16 (br, 8H, ArH), 8.32 (br,
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4H, ArH), 8.84 (m, 8H, β-H). UV-Vis (DMSO) λmax: 419 nm (ε 395,100), 514 (17,200),
549 (8,300), 589 (5,900), 645 (4,900). The HRMS of 2.6d is shown in Figure 2-17.

Figure 2-16: 5,10-bis-(4-phosphonate diethylester)-15,20-bis[(3,5-(1-methyl-ocarboranylmethyl)phenyl]porphyrin 2.6b in CD2Cl2 at 300 MHz

Figure 2-17: HRMS of phosphonic acid porphyrin 2.6d
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• 5-(4-Dimethylaminophenyl)-10,15,20-tris[3,5-(2-methyl-o-carboran-1-

yl) methylphenyl] porphyrin (2.7a)

This porphyrin was obtained in 6.3% yield as a red/brown solid. M.p. >300 oC;
MS (MALDI) m/z 1679.10 [M]+; 1H NMR (CD2Cl2) δ ppm: -2.73 (s, 2H, NH),
1.25-3.1 (br, 60H, BH), 2.27 (s, 18H, CH3), 3.29 (s, 6H, CH3), 3.85 (s, 12H,
CH2), 7.20 (br, 2H, ArH), 7.57 (s, 3H, ArH), 8.12-8.16 (m, 8H, ArH), 8.90 (br,
6H, β-H), 9.10 (br, 2H, β-H). UV-Vis (DMSO) λmax: 418 nm (ε 253,900), 518
(14,300), 562 (11,000), 592 (8,100), 653 (6,300). Quaternization afforded the
corresponding quaternary ammonium iodide salt (2.7c) in 92% yield as purple
red solid. M.p. 186.3 oC; HRMS (ESI) m/z 1695.7502 [M + H – I]+, calculated
for C71H122B60N5 1694.5730; 1H NMR (acetone-d6) δ ppm: -2.78 (s, 2H, NH),
1.25-3.1 (br, 60H, BH), 2.38 (s, 18H, CH3), 4.09 (s, 12H, CH2), 4.28 (s, 9H,
CH3), 7.85 (s, 3H, ArH), 8.23 (s, 6H, ArH), 8.60 (s, 4H, ArH), 8.92 (m, 8H, βH); UV-Vis (DMSO) λmax: 420 nm (ε 389,800), 514 (14,900), 548 (7,700), 588
(5,800), 644 (4,400). The HRMS of compound 2.7c is shown in Figure 2-18.

Figure 2-18: HRMS of phosphonic acid porphyrin 2.7c
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5-(4-Phosphonate diethyl ester)-10,15,20-tris[(3,5-(2-methyl-o-carboran-1yl)methyl phenyl]porphyrin (2.7b):

•

This porphyrin was obtained in 8.0% yield as a purple solid. M.p. 294.7 oC; MS
(MALDI) m/z 1756.10 [M – CH3]+; 1H NMR (CD2Cl2) δ ppm: -2.80 (br, 2H, NH), 1.36
(t, 6H, CH3, J = 7.0 Hz), 1.3 – 3.4 (br, 60H, BH), 2.28 (s, 18H, CH3), 3.86 (s, 12H, CH3),
4.38 (m, 4H, CH2), 7.59 (s, 3H, ArH), 8.12 (s, 6H, ArH), 8.26 (m, 2H, ArH), 8.41 (m,
2H, ArH), 8.97 (m, 8H, β-H) as shown in Figure 2-19. UV-Vis (CH2Cl2) λmax: 419 nm (ε
359,100), 514 (21,900), 548 (11,000), 588 (7,400), 643 (3,500). Deprotection afforded
the corresponding phosphonic acid porphyrin (2.7d) in 94% yield as a black solid. M.p.
>300

o

C; HRMS (ESI) m/z 1717.4781 [M+H]+, calculated for C68H115B60N4O3P

1716.4735; 1H NMR (DMSO-d6) δ ppm: -2.91 (s, 2H, NH), 2.24 (s, 18H, CH3), 1.3 – 3.4
(br, 60H, BH), 3.92 (s, 12H, CH2), 7.68 (br, 3H, ArH), 8.12 (br, 8H, ArH), 8.26 (br, 2H,
ArH), 8.86 (br, 8H, β-H). UV-Vis (DMSO) λmax: 420 nm (ε 418,100), 515 (16,900), 549
(8,000), 589 (5,700), 645 (4,700). The HRMS of compound 2.7d is shown in Figure 2-20.

Figure 2-19: 5-(4-phosphonate diethylester)-10,15,20-tris[(3,5-(1-methyl-ocarboranyl)phenyl]porphyrin 2-7b in CD2Cl2 at 300 MHz
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Figure 2-20: HRMS of phosphonic acid porphyrin 2.7d
5,10,15-Tris-(4-phosphonate diethyl ester)-20-bis[(3,5-(2-methyl-o-carboran1-yl) methylphenyl]porphyrin (2.8b):

•

This porphyrin was obtained in 4.5% yield as a purple solid. M.p. 267 oC; MS (MALDI)
m/z 1362.40 [M]+; 1H NMR (CD2Cl2) δ ppm: -2.83 (br, 2H, NH), 1.55 (t, 18H, CH3, J =
7.0 Hz), 1.3 – 3.4 (br, 20H, BH), 2.27 (s, 6H, CH3), 3.84 (s, 4H, CH2), 4.40 (m, 12H,
CH3), 7.58 (s, 1H, ArH), 8.08 (s, 2H, ArH), 8.26 (m, 6H, ArH), 8.42 (m, 6H, ArH), 8.97
(m, 8H, β-H) as shown in Figure 2-21. UV-Vis (CH2Cl2) λmax: 419 nm (ε 385,000), 514
(16,300), 549 (6,700), 589 (5,000), 643 (3,000). Deprotection afforded the corresponding
phosphonic acid porphyrin (2.8d) in quantitative yield as a blue-green solid. M.p.: > 300
o

C; HRMS (ESI) m/z 1196.5739 [M+H]+, calculated for C52H61B20N4O9P3 1195.5655; 1H

NMR (DMSO) δ ppm: -2.94 (br, 2H, NH), 1.3 – 3.4 (br, 20H, BH), 2.27 (s, 6H, CH3),
3.96 (br, 4H, CH2), 7.72 (s, 1H, ArH), 8.08-8.16 (m, 8H, ArH), 8.31-8.34 (m, 6H, ArH),
8.84 (br, 8H, β-H). UV-Vis (DMSO) λmax: 420 nm (ε 331,700), 515 (14,600), 549
(7,100), 589 (5,100), 645 (4,200). The HRMS of compound 2.8d is shown in Figure 2-22.
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Figure 2-21: 5,10,15-Tris-(4-phosphonate diethylester)-20-bis[(3,5-(1-methyl-ocarboranyl)phenyl]porphyrin 2.8b in CD2Cl2 at 300 MHz

Figure 2-22: HRMS of phosphonic acid porphyrin 2.8d
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2.5.2. Molecular Structures
Crystal structures were determined using data collected at low temperature on a Nonius
Kappa CCD diffractometer equipped with MoKα radiation (λ=0.71073 Å) and a graphite
monochromator. Refinement was by full-matrix least squares, and all nonhydrogen atoms
were treated anisotropically with H atoms included, except as described below.
Crystallographic data (excluding structure factors) for the structures in this paper have
been deposited with the Cambridge Crystallographic Data Centre as supplementary
publications no. CCDC 663420-663423, CCDC 663925 and CCDC 644633. Copies of
the data can be obtained, free of charge, on application to CCDC, 12 Union Road,
Cambridge,

CB2

1EZ, UK,

(fax:

+44- (0)1223-336033

or

e-mail:

deposit

@ccdc.cam.ac.uk).
Crystal data for 2.1: colorless, C9H7Br2N, Mr=289.0, monoclinic space group P21/c,
a=7.574(2), b=4.4039(10), c=28.315(8) Å, β=96.475(8)˚, V=938.4(4) Å3, Z=4,
ρcalcd=2.045 gcm-3, µ=8.579 mm-1, T=90K, 8408 data collected, R=0.021 (F2>2σ),
Rw=0.050 (all F2) for 2279 unique data having θ<28.2˚ and 110 refined parameters.
Absorption corrections by multi-scan method.
Crystal data for 2.2: colorless, C15H33B20N, Mr=443.6, monoclinic space group P21/n,
a=17.526(2), b=7.8927(10), c=20.262(3) Å, β=109.743(6)˚, V=2638.0(6) Å3, Z=4,
ρcalcd=1.117 gcm-3, µ=0.052 mm-1, T=150K, 21359 data collected, R=0.071 (F2>2σ),
Rw=0.202 (all F2) for 5089 unique data having θ<27.1˚ and 328 refined parameters.
Crystal data for 2.3: colorless, C15H34B20O, Mr=446.6, orthorhombic space group
P212121, a=7.8923(10), b=12.211(2), c=27.548(5) Å, V=2654.9(7) Å3, Z=4, ρcalcd=1.117

60

gcm-3, µ=0.054 mm-1, T=110K, 22125 data collected, R=0.050 (F2>2σ), Rw=0.143 (all
F2) for 4549 unique data having θ<30.5˚ and 327 refined parameters.
Crystal data for 2.4a: tan, C17H19N3, Mr=265.4, monoclinic space group P21/n,
a=8.0907(10), b=8.735(2), c=20.075(4) Å, β=96.093(12)˚, V=1410.7(5) Å3, Z=4,
ρcalcd=1.249 gcm-3, µ=0.075 mm-1, T=110K, 22814 data collected, R=0.045 (F2>2σ),
Rw=0.121 (all F2) for 5080 unique data having θ<32.5˚ and 189 refined parameters.
Crystal data for 2.5b: brown, C68H104B40N4O6P2 . 3 C7H8, Mr=1844.3, monoclinic
space group C2/c, a=25.249(7), b=22.017(6), c=19.894(5) Å, β=105.52(2)˚, V=10656(5)
Å3, Z=4, ρcalcd=1.150 gcm-3, µ=0.092 mm-1, T=110K, 48441 data collected, R=0.112
(F2>2σ), Rw=0.343

(all F2) for 7630 unique data having θ<23.3˚ and 569 refined

parameters. All toluene solvent molecules are disordered, and were treated in halfpopulated sites with isotropic C atoms and a common Uiso for each molecule. Solvent H
atoms were not included.
Crystal data for 2.6a: Black, C64H96B40N6 . 4 CHCl3, Mr=1859.3, triclinic space group
P-1,

a=11.3640(12),

b=18.753(2),

c=23.905(4)

Å,

α=85.692(5),

β=86.915(5),

γ=73.912(6)˚, V=4878.1(11) Å3, Z=2, ρcalcd=1.266 gcm-3, µ=0.384 mm-1, T=106K, 11914
data collected, R=0.171 (F2>2σ), Rw=0.457 (all F2) for 7736 unique data having θ<20.0˚
and 573 refined parameters. Due to the very weak scattering power of the crystals even at
low temperature, it was not possible to do full anisotropic refinement. Only the Cl atoms
were refined anisotropically, while the lighter atoms were treated as isotropic.
2.5.3. Absorption and Emission Spectra
The absorption spectra were measured on a Perkin Elmer Lambda 35 UV-vis
spectrometer with 10 mm path length quartz cuvettes equipped with a photodiode
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detector, in the 300-700 nm wavelength range with 0.1 nm accuracy. Emission spectra
were obtained on a Perkin Elmer LS55 luminescence spectrophotometer equipped with a
Xenon lamp, in the 500-700 nm wavelength range with 1 nm accuracy. Stock solutions of
all porphyrins in DMSO at 1 x 10-4 M were prepared. The aqueous solutions were
prepared by adding 100 µL of each porphyrin DMSO stock solution into 10 mL of
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethansulfonic acid) buffer, 20 mM, pH 7.4.
All measurements were performed within 2 h of solution preparation.
2.6. Alternate Methods
Alternative routes to trimethylamine-substituted carboranylporphyrins were attempted.
The following synthetic schemes detail these efforts.
2.6.1. Method One
The synthetic scheme to compound 2.14 is detailed in Scheme 2.2. This particular
scheme was chosen because of the literature precedent leading to compound 2.3.1, 2, 9 It
was hoped that porphyrin 2.13 could be obtained in high yields and be an invaluable
precursor to a series of carboranylporphyrins functionalized with water-solubilizing
groups, including amines, carboxylic acids, and phosphonic acids.

•

1-Bromo-3,5-bis-bromomethyl-benzene (2.10) To a 500ml three-necked round

bottom flask (RBF) was added 300 mL carbon tetrachloride (CCl4), n-bromosuccinimide
(NBS) (9.79 g, 55 mmol), benzoyl peroxide (0.80 g, 3.3 mmol), and degassed with
nitrogen for fifteen minutes. 1-Bromo-3,5-dimethyl-benzene 2.9 (4.63 g, 25 mmol) was
syringed into the reaction vessel which was then gradually heated to reflux while stirring
under argon. The reaction appears light yellow and cloudy and not all of the NBS
dissolves upon initial reflux. The reaction was monitored by TLC (1:4 EtOAc/Hexanes,
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silica). After sixteen hours, TLC indicates that all the starting material is gone. White
solids are present on the wall of the reaction vessel. After cooling the reaction to 0 oC in
an ice bath, the reaction mixture was poured through coarse, fast-flow filter paper and
washed once with NaHCO3 and once with distilled water.

The organic phase was

separated and dried over Na2SO4, filtered, and the solvent removed under reduced
pressure. The resulting yellow residue was purified by column chromatography using
ethyl acetate/hexane 1/9 for elution. The desired product was isolated and recrystallized
from n-hexanes, yielding 2.83 g (33 % yield) of the title compound. 2.10. MS (EI) m/z
42.8, 1H NMR (CDCl3) δ ppm:

4.40 (s, 4H, CH2), 7.34(s, 1H), 7.47 (s, 2H), in

agreement with literature. The 1H-NMR spectra of compound 2.9 can be seen in Figure 223. (Note the downfield shift of the brominated methylenes.)

Figure 2-23: 1H-NMR spectrum of 1-Bromo-3,5-bis-bromomethyl-benzene 2.10 in
CDCl3 at 300 MHz
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Scheme 2-2: (i) NBS, benzoyl peroxide, CCl4, reflux, 1 hr (33%); (ii) 1-Lithium-2methyl-o-carborane, THF, LiI, rt, 20 hr (61%); (iii) n-BuLi, THF, -78 oC; (iv) DMF, -78
o
C; (v) 10% HCl, 0 oC (30% over three steps); (vi) pyrrole, TFA, rt (99%); (vii) 4Bromobenzaldehyde, TFA, CH2Cl2, rt; (viii) p-chloranil, rt (2%)

•

Bis[3,5-(1-methyl-o-carboranyl)methyl]bromobenzene (2.11) n-Butyllithium

(0.19 mL, 1.6 M in hexane) was added drop wise to a solution of 1-methyl-o-carborane
(0.050 g, 0.32mmol) in dry THF (5 mL) at a temperature between –5 and 0 oC, under
Argon. The mixture was stirred at this temperature for 1.5 hours, then compound 2.10
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(0.050 g, 0.15 mmol) in THF (4 mL) was added and the final reaction mixture allowed to
warm to room temperature and stirred for 16 hours. A bright yellow color is observed
upon addition of compound 2.10. After quenching the reaction with water, the resulting
mixture was extracted three times with diethyl ether. The organic extracts were washed
once with water, once with brine, and dried over Na2SO4. The organic solution was then
filtered and the solvent removed under reduced vacuum. A bright yellow solid remains
which was dried onto silica and chromatographed using IntelliFlash chromatography. The
crude material was chromatographed in 1:4 EtOAc/ Hexane over ten minutes and the
collected fractions rotovaped to yield the title compound 2.11 as a white solid (44 mg, 61
%). MS (EI) m/z 446.4; 1H NMR (CDCl3) δ ppm 1.4–3.0 (br, 20H, BH), 2.17 (s, 6H,
CH3), 3.43 (s, 4H, CH2), 6.96 (s, 1H), 7.31 (s, 2H), in agreement with literature. The 1HNMR of compound 2.11 is shown below in Figure 2-24. (Note the upfield shift of the
methylenes after carboranyl substitution at the bromine positions.)

Figure 2-24: 1H-NMR spectrum of bis[3,5-(1-methyl-o-carboranyl)methyl]bromobenzene 2.11 in CDCl3 at 300 MHz
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•

Bis[3,5-(1-methyl-o-carboranyl)methyl]benzaldehyde (2.3) A solution of

compound 2.11 (0.30 g, 0.60 mmol) in dry THF (6 mL) under Argon was cooled to –78
o

C. n-Butyllithium (0.42 mL, 1.6 M in hexane) was added drop wise via syringe. After

stirring the reaction mixture for 30 minutes at –78 oC, dry DMF (0.23 mL, 0.66 mmol)
was slowly added. The resulting bright yellow mixture was stirred at –78 oC for 30
minutes then warmed to 0 oC and stirred at this temperature for 1 hour. A 5 % aqueous
HCl solution (2 mL) was added and the final mixture stirred at room temperature for 15
minutes. The organic solvent was removed under reduced pressure and the aqueous

Figure 2-25: 1H-NMR spectrum of bis[3,5-(1-methyl-o-carboranyl)methyl]benzaldehyde
2.3 in CDCl3 at 300 MHz

phase extracted three times with EtOAc. It was necessary to add brine to the aqueous
phase in order to clear an emulsion which appeared between the aqueous and organic
phases. The organic phase was then dried over Na2SO4, filtered, and the solvent removed
under vacuum to provide a clear, viscous residue. The crude material was dried onto
silica and chromatographed using IntelliFlash chromatography and eluted using 1:3
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EtOAc/ hexane over 20 minutes. The eluted fractions were collected and the solvent
evaporated to afford the title compound 2.3 (0.80 g) as a white solid in 30 % yield. MS
(EI) m/z 446.4; 1H NMR (CDCl3) δ ppm: 1.5-3.0 (br, 20H, BH), 2.20 (s, 6H, CH3), 3.55
(s, 4H, CH2), 7.30 (d, 1H, J = 1.6 Hz), 7.67 (d, 2H, J = 1.6 Hz), 10.03 (s, 1H, CHO), in
agreement with literature and as shown in Figure 2-25.

•

5-{Bis[3,5-(1-methyl-o-carboranyl)methyl]phenyldipyrromethane (2.12) A

clear solution of compound 2.3 (0.380 g, 0.85 mmol) and freshly distilled pyrrole (3.5
mL, 51 mmol) was purged with Argon for five minutes. A catalytic amount of TFA
( 8µL, 0.10 mmol) was syringed into the reaction vessel and the final solution was stirred
at room temperature under Argon. The solution begins to turn light yellow in color after
a few minutes.

TLC (1:3 EtOAc/hexane) indicates the reaction complete after ten

minutes. The crude material was dried onto silica and chromatographed using IntelliFlash

Figure 2-26: 1H-NMR spectrum of 5-{bis[3,5-(1-methyl-o-carboranyl)methyl]phenyldipyrromethane 2.12 in CD2Cl2 at 300 MHz
chromatography and eluted using a gradient 15-60 % dichloromethane/hexane over 50
minutes. The eluted fractions were collected and the solvent evaporated to afford the title
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compound 2.12 (0.51 g) as a yellow solid in quantitative yield. NOTE: Product is air
sensitive and immediately turns from white to yellow once vacuum is released on the
solvent evaporator. If left in dichloromethane solution it will decompose and its color
will change from yellow to green to black. Decomposition is observed on TLC as
increasingly non-polar decomposition products. MS (MALDI) m/z 563.5; 1H NMR
(CD2Cl2) δ ppm: 1.5-2.9 (br, 20H), 2.17 (s, 6H, CH3), 3.51 (s, 4H, CH2), 5.56 (s, 1H,
CH), 5.90 (br, 2H, β-pyrrole-H), 6.17-6.20 (m, 2H, β-pyrrole-H), 6.78-6.80 (m, αpyrrole-H), 7.00 (s, 1H, p-ArH), 7.06 (s, 2H, o-ArH), 8.11 (br, 2H, NH) as shown in
Figure 2-26.

•
5,15-bis(4-bromophenyl)-10,20-bis[,5-(1-methyl-o-carboranyl-methyl)phenyl]
porphyrin (2.13):
Compound 2.13 was synthesized using the MacDonald [2+2] method previously
discussed in Chapter 1. In MacDonald condensation reactions there are a number of
variables to consider including amount and type of acid, reaction time, and oxidizing
agent. Table 2-1 summarizes the reaction conditions used to prepare 2.13.
Table 2.1: Summary of reaction conditions for compound 2.13
Experiment

Catalyst
(molar equiv.)

1

TFA,
(0.1, 0.3, 0.75)

2

BF3(OEt)2,
(0.1, 0.75)

Oxidizing Agent,
time

Reaction Time Product Yield

p-chloranil, 6 hr

1, 13 hr

2%

DDQ,

1, 13 hr

>1%

30 min

For porphyrin 2.13, a stoichiometric or catalytic amount of TFA or boron trifluoride
diethyletherate was chosen for all experiments. Reaction times were varied between one

68

and thirteen hours and the oxidizing agent employed was either DDQ or p-chloranil.
Based upon TLC and MALDI analyses, product scrambling is responsible for the low
yield. The reaction conditions, which produced the desired product in the greatest yield
(2%), employed a catalytic amount of TFA (0.1) over a 13 hr reaction time, followed by
p-chloranil oxidation over 6 hrs. Given the poor yields obtained of porphyrin 2.13, this
synthetic method was abandoned. M.p. > 300 oC; MS (MALDI) m/z 1456.19 [M + 1]+ as
shown in Figure 2.27; 1H NMR (CDCl3) δ ppm: -2.83 (br, 2H, NH), 1.3 – 3.4 (br, 40H,
BH), 2.27 (s, 12H, CH3), 3.84 (s, 8H, CH2), 7.11 (bs, 4H, ArH), 7.48 (bs, 4H, ArH), 8.87
(bs, 8H, β-H). UV-Vis (CH2Cl2) λmax: 416 nm (ε 325,610), 512 (11,245), 546 (6,100),
589 (3,341), 645 (2,785).

Figure 2-27: MALDI MS of 5,15-bis(4-bromophenyl)-10,20-bis[3,5-(1-methyl-ocarboranyl-methyl)phenyl] porphyrin (2.13)
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2.6.2. Method Two
Given some of the poor overall yields associated with Scheme 2-2, an effort was made to
design a synthetic scheme, which would ultimately lead to a more efficient synthesis. The
principle difference in Scheme 2-3 is the preparation of the dipyrromethane 2.15. The
advantage of using a p-acetamidophenyl functionality over a p-bromophenyl
functionality (Scheme 2-2) is in having the protected amine already attached to the

O
HN

Me
Me

Me

i,ii,iii,iv

+ (2)

(2)

CHO

NH HN

2.3

2.15
NH2
Me

Me
NH

Me

Me

N

N

N
Cu

N

HN

N
Me

Me

N
Me

Me

NH2

NH2

2.16 (1.0%)

2.17 (2.2%)

Scheme 2-4: (i) TFA, CH2Cl2, rt, 13h; (ii) DDQ, 30 min; (iii) EtOH/HCl (3:2), reflux,
24h; (iv) Cu(OAc)2, CH2Cl2/MeOH (10:1), rt, 48h (Compound 2.17, only)

porphyrin macrocycle. This pre-functionalized porphyrin alleviates the need to perform
the additional palladium coupling procedure. Using the MacDonald [2 + 2] method,
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condensation of the porphyrin was performed, followed by plug purification and acid
hydrolysis of the acetyl group. As can be seen in Scheme 2-3, the desired A2B2
porphyrin 2.16 was synthesized along with an unexpected corrole product 2.17. What is
surprising is that the corrole is the major product, having been isolated in 2 % compared
to the porphyrin at 1 % yield. The low yield of the porphyrin is disappointing and
indicates that this particular synthetic scheme is an inefficient route towards the total
synthesis of the target compound 2.14. The isolation of the corrole product opens up the
possibility that a synthetic scheme may be developed for its synthesis and similar
corroles. The 1H-NMR of compounds 2.15 and 2.17 are shown in Figures 2-28 and 2-29,
respectively.

•

5-(4-Acetamido)phenyldipyrromethane (2.15) The synthesis of this compound

proceeded as previously described above and resulted in a yellow solid in 73 % yield. MS
(MALDI) m/z 280.4; 1H NMR (CD2Cl2) δ ppm: 2.21 (s, 3H, CH3), 5.46 (s, 1H, CH), 5.90
(br, 2H, β-pyrrole-H), 6.21 (s, 2H, β-pyrrole-H), 6.77 (s, α-pyrrole-H), 7.25 (m, 2H, mArH), 7.46 (s, 2H, o-ArH), 8.21 (br, 2H, NH) as shown in Figure 2-28.

Figure 2-28: 1H-NMR spectrum of 5-(4-acetamido)phenyldipyrromethane 2.15 in
CD2Cl2 at 300 MHz
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5,15-(4-aminophenyl)-10,20-bis[3,5-(1-methyl-o-carboranylmethyl)phenyl]
porphyrin (2.16):

•

m.p. > 300 oC; MS (MALDI) m/z 1324 [M - 1]+; 1H NMR (CD2Cl2) δ ppm: -2.75 (br,
2H, NH), 1.3 – 3.4 (br, 40H, BH), 2.24 (s, 12H, CH3), 3.82 (s, 8H, CH2), 4.16 (bs, 4H,
NH2), 7.13 (bs, 4H, ArH), 7.55 (s, 2H, p-ArH), 8.03 (bs, 4H, ArH), 8.10 (s, 4H, ArH),
8.87 (bs, 4H, β-H), 9.06 (bs, 4H, β-H). UV-Vis (CH2Cl2) λmax: 424 nm (ε 303,017), 472
(12,551), 519 (6,200), 559 (5,882), 651 (2,399).

•
Cu(II)-5-(4-aminophenyl)-10,15-bis[3,5-(1-methyl-o-carboranylmethyl)phenyl] corrole (2.17):
m.p. > 300 oC; MS (MALDI) m/z 1281 [M - 1]+; 1H NMR (CD2Cl2) δ ppm: 1.3 – 3.4
(br, 40H, BH), 2.27 (s, 12H, CH3), 3.67 (s, 8H, CH2), 6.85 (bs, 2H, ArH), 7.35 (s, 2H, pArH), 7.41 (bs, 2H, β-H), 7.48 (bs, 2H, β-H), 7.58 (bs, 2H, Ar-H), 7.65 (s, 4H, β-H), 7.70
(bs, 2H, β-H), 8.04 (bs, 2H, NH2). UV-Vis (CH2Cl2) λmax: 416 nm (ε 238,467), 540
(9,435), 626 (2,295).

Figure 2-29: The 1H-NMR spectrum of corrole 2.17 in CD2Cl2 at 300 MHz
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2.6.3. Additional Methods
The following schemes and tables summarize additional methods to synthesize
trimethylamine-substituted carboranylporphyrins. The methods did not result in the
formation of desired product, but serve to inform the reader as to the challenging nature
of porphyrin synthesis.
With the exceptions of acid catalyst and oxidizing reagents chosen, the method
outlined in Scheme 2-5 employs identical reaction conditions and starting reagents to
those found in Scheme 2-1. The outcome, however, is remarkably different for Scheme 25 as no product(s) were isolated. The choice of oxidizing agent was not as significant as
the choice of acid catalyst. In the case of Scheme 2-5, the choice of a protic acid versus a
Lewis acid determined whether the product formed.
Table 2.2: Reaction conditions for compound 2.5a
Experiment

Acid Catalyst

Oxidizing Agent,
time

Reaction
Time

Product Yield (%)

1

TFA,

p-chloranil,

1,13 hr

0

0.1, 1.25, 2.5 eq

6 hr

p-TsOH,

p-chloranil,

1,13 hr

>1

0.1, 0.6, 1.1 eq

6 hr

2

In the case of Scheme 2-6 the reason for failing to form the desired is not clear. As Table
3 indicates both a protic and a Lewis acid were used as acid catalysts in the reaction;
however, similar to Scheme 2-5, no product formed. Normally, protonation of the
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(2)
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2.4a

= BH
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Me

Me

N

Me2N

HN

NH

NMe2

N

Me

Me
2.5a

Scheme 2-5: (i) acid catalyst, CH2Cl2, rt; (ii) oxidizing agent, rt

Table 2.3: Reaction conditions for compound 2.5a
Experiment

Acid Catalyst

Oxidizing Agent,
time

Reaction
Time

Product Yield (%)

1

TFA,

p-chloranil,

1,13 hr

0

0.1, 1.0, 2.5 eq

6 hr

BF3(OEt)2,

DDQ,

1,13 hr

0

0.1, 1.0 eq

6 hr

2
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dimethylamine would result in a highly electrophilic aldehyde and the condensation
would proceed efficiently. This clearly was not the case, however. It may be that the
dimethylamine reaches an equilibrium state between tertiary and quaternary states under
protic or Lewis acid conditions, which causes the aldehyde to be alternately nonelectrophilic and electrophilic. Such an occurrence may prohibit the formation of the
porphyrinogen species.

Me

Me

i,ii

NMe2

(2)

+
NH HN
2.17

= BH
=C

//

(2)
CHO
2.18

Me

Me

N

Me2N

HN

NH

NMe2

N

Me

Me
2.5a

Scheme 2-6: (i) acid catalyst, CH2Cl2, rt; (ii) oxidizing agent, rt
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Chapter 3
Alternative Methods for the Symmetric and Asymmetric Syntheses of Porphyrins
and Carboranylporphyrins
3.1 Introduction
The porphyrin syntheses presented in the previous chapter relied exclusively on
MacDonald [2 + 2] methodology and its well-documented acidolytic scrambling of
porphyrinogen intermediates.1-4 While the isolation of multiple products is conducive to
SAR studies, clearly there is a need to develop a synthetic methodology that reduces or
eliminates acidolytic scrambling, extensive column chromatography, and which results in
the isolation of a single product in improved yield. Furthermore, this new synthetic
scheme should be amenable to a high degree of functionalization of the porphyrin at the
meso-periphery in order to achieve the necessary amphiphilic properties discussed in the
previous chapter and to have widespread application in PDT and BNCT. An extensive
search of the literature suggested a few possible synthetic avenues, which are the subject
of this chapter and which represent a paradigm shift in the strategy for porphyrin
preparation presented thus far in this dissertation.
3.2 Results
3.2.1 Synthesis of 5,15-substituted Porphyrins
The synthesis begins with the preparation of dipyrromethane (3.2) in 28% yield using
pyrrole (1.5), p-formaldehyde (3.1), and a catalytic amount of TFA as outlined in Scheme
3.1.5 The X-ray structure of dipyrromethane 3.2 can be seen in Figure 3.1. The
dipyrromethane (3.2) was then condensed with aldehydes Ra-Re using the MacDonald [2
+ 2] method and subsequently oxidized with DDQ to produce the 5,15-substituted
porphyrins 3.3 to 3.7 in 66, 51, 22, 18, and 46% yield, respectively.

78

O
N
H
1.5

+

H H

TFA
n

NH HN
3.2

0C,

70
5 min
(28 %)

3.1

= BH
=C

Me

Me

Ra=

MeO

Rc=

Rb=

B(OH)2

Br

OMe

Re=

Rd=

R

(2)

NH HN
3.2

1) TFA, CH2Cl2, rt, 18 h
+ (2) Ra, b, c, d, e
( as aldehyde ) 2) DDQ, CH2Cl2, rt, 1 h

N

NH

HN

N

3.3: R=Ra (66%)
3.4: R=Rb (51%)
3.5: R=Rc (22%)
3.6: R=Rd (18%)
3.7: R=Re (46%)

R

Scheme 3-1: Syntheses of 5, 15-substituted porphyrins
(Note: No chromatography required.)

O
HN
N
R f=

O
O P O

CH3
Rh=

Rg=

R

(2)

NH HN
3.2

+

(2) Rf - Rh
(as aldehyde)

1) TFA, CH2Cl2, rt, 18 h

NH

2) DDQ, CH2Cl2, rt, 1 h

N

N
HN

3.8: R = Rf (0%)
3.9: R = Rg (0%)
3.10: R = Rh (0%)

R

Scheme 3-2: Unsuccessful syntheses of 5, 15-substituted porphyrins
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There was no TLC or UV-Vis evidence to indicate acidolytic scrambling and the
formation of additional porphyrin products. Each porphyrin was isolated in pure form
without the need for column chromatography by simply washing with polar solvents and
filtering. An effort was made to extend the synthetic method to aldehydes Rf - Rh which
resulted in no isolated porphyrin product as indicated in Scheme 3.2.
3.2.2 Metalation, Bromination, and Demetalation of 5,15-substituted Porphyrins
5,15-Substituted porphyrins 3.3, 3.4, and 3.7 underwent metal insertion using
zinc(II)acetate (3.3, 3.4) or nickel(II) acetate (3.7) in a refluxing solution of DMF and
pyridine over a period of 2 h as shown in Scheme 3-3 (Method 3).6-8 The final metalated
porphyrin products were obtained in 77 – 92 % yield with no chromatography
required. Figure 3.2 shows the X-ray structure of Zn(II)-5,15-[3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.8). Methods 1 and 2 utilized different solvent
schemes from Method 3 and required longer reaction times and column chromatography.9
Porphyrins 3.8 to 3.10 were subsequently brominated at the 10,20-meso positions
using a solution of NBS, pyridine, and chloroform at 0 oC.8, 10 The radical reaction was
quenched with acetone after 20 minutes and the products (3.11 to 3.13) were washed,
filtered, dried, and isolated in 86 – 93% yield. Once again, no column chromatography
was required. The X-ray structure of 5,15-bromo-10,20-(3,5-methoxyphenyl)porphyrin
(3.12) is shown in Figure 3-3 with a single molecule of THF coordinated to the zinc atom
at the porphyrin’s center.
Porphyrins 3.11 and 3.12 underwent successful demetalation using a solution of TFA
in dichloromethane. The products were washed and vacuum filtered to produce
porphyrins 3.14 and 3.15 in 97-99 % yield. No chromatography was required. Efforts
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were made to demetalate porphyrin 3.13, but the inserted nickel could not be removed
using standard methods. Decomposition resulted when a stronger acid, sulfuric acid, was
used in the demetalation reaction.11
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Scheme 3-3: Metalation, meso-bromination, and demetalation of 5,15-substituted
porphyrins. (Note: No chromatography required for all three steps.)
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3.2.3 Formation of Carboranylporphyrin Boronic Acids
Three methods were investigated for the purpose of forming boronic acid derivatives at
the 10,20-meso-positions of 5,15-dibromo-carboranylporphyrin 3.11 as depicted in
Scheme 3-4.12,

13

In the first method porphyrin 3.15, bis(pinacolato)diboron, trans-

dichlorobis(triphenylphosphine)palladium (II), pyridine or triethylamine, were heated in
1,2-dichloroethane and resulted in the formation of the dehalogenated compound 3.8. A
similar result occurred in the second method using pinacolborane. The third method,
using n- butyllithium resulted in the decomposition of the porphyrin macrocycle.
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Scheme 3-4: Methods toward the formation of boronic acids of carboranylporphyrins
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3.2.4 Nucleophilic Additions to 5,15-substituted Porphyrins
A effort was made to synthesize trans-A2B-substituted porphyrins using 4-bromo-N,Ndimethylaniline and n-butyllithium as shown in Scheme 3-5. In the case of compound
3.8, there is no evidence of a nucleophilic addition occurring, according to TLC, UVVis, or 1H-NMR analysis. The starting material was recovered. When the zinc metal was
removed, as in the case of compound 3.4, the reaction was successful and yielded 34%
NMe2
Me
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Br
N

N

H

Zn

H

N

N

Me

1) n-BuLi
THF/Et2O, -78 oC
2) H2O
3)DDQ
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Me

3.8
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MeO

OMe

MeO

OMe
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N
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H

H
N

HN

1) n-BuLi
THF/Et2O, -78 oC
2) H2O
3)DDQ

NH

N
NMe2

H
N

HN

(confirmed by H-NMR, MS)
(35 %)

MeO

OMe

MeO

3.4

OMe
3.16

Scheme 3-5: Organolithium additions of porphyrins
of mono-addition product after first quenching the reaction with water and oxidizing with
DDQ. Column chromatography was required.
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3.2.5 Suzuki Cross-coupling Reactions of Metal-free 5,15-substituted Porphyrins
An effort was made to synthesize trans-A2B2 porphyrins via a Suzuki coupling method as
outlined in Scheme 3-6. Compound 3.17 was successfully synthesized in 74 % yield in
three steps from compound 2.11 using n-butyllithium and trimethylborate, followed by
acidic hydrolysis in aqueous HCl. The cross-coupling reaction with porphyrin 3.15
yielded the mono-coupled product 3.18 in 12 % yield as confirmed by TLC, UV-Vis, HNMR, and MALDI-TOF mass spectroscopy.
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Scheme 3-6 Suzuki coupling of metal-free porphyrin 3.15
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3.2.6 Preparation of 5,10,15,20-tetrakis-(4-phosphenatophenyl)Porphyrin (3.20)
The preparation of porphyrin 3.20 was investigated using three different methods as
outlined in Scheme 3-7. In the first method the diester intermediate form of porphyrin
3.19 was prepared using Adler-Longo conditions and resulted in the isolation of the
PO(OEt)2
(4)

+
N
H
1-5

CH3CH2COOH
150 oC, 1.5 h
(6 %)

(4)
CHO

3.19

1) TFA, CH2Cl2, rt, 18 h
2)DDQ, rt, 1h

1) TmsBr, CH2Cl2, rt, 24 h
2)1:4 H2O/THF, 2 h
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(HO)2OP

N
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PO(OH)2
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Scheme 3-7: Preparation of H2TPPP 3.20
desired product in 6% yield. When condensing the pyrrole and aldehyde with TFA
instead of propionic acid in the second method, no intermediate ester product could be
isolated. When a pre-functionalized dipyrromethane 2.4b was condensed with 4formylphenyl phosphonate using a Lewis acid, the intermediate ester was isolated in 4%
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yield. In the final step, the ester was hydrolyzed via a trimethylsilylether intermediate and
cleaved under aqueous conditions to produce H2TPPP 3.20 in quantitative yield.

Figure 3-1: X-ray crystal structure of dipyrromethane 3.2

Figure 3-2: X-ray crystal structure of Zn(II)-5,15-bis[bis-3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.8)
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Figure 3-3: X-ray crystal structure of Zn(II)-5,15-Bromo-10,20-(3,5methoxyphenyl)porphyrin (3.12) Note: THF solvent is coordinated to zinc metal
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3.3 Discussion
In the MacDonald [2 + 2] method employed in the previous chapter, the synthetic
strategy utilized a “pre-functionalized” dipyrromethane intermediate with a pphosphonate ester- or a p-dimethylaminophenyl-substituent at the 5-position of the
dipyrromethane. After condensation the resulting 5,10,15,20-substituted porphyrins
require an additional one or two synthetic steps before obtaining the desired final
products. If it were not for acidolytic scrambling, extensive chromatography, and poor
yields associated with the condensation of these two series of porphyrins, this synthetic
protocol would be ideal. However, this was not the case, and this fact has lead to an
investigation of alternative methods for the formation of porphyrins.
Recall from Chapter 1 that in the MacDonald [2 + 2] method, the dipyrromethane is in
equilibrium with itself and with intermediates under acidic conditions as the condensation
reaction progresses towards the formation of the porphyrinogen. The macrocycle results
when the equilibrium is shifted towards the porphyrinogen, rather then when it is shifted
towards the formation of starting materials or polypyrrolic species. An important factor
influencing this equilibrium is the substituent at the 5-position of the dipyrromethane. In
the case of the two series of porphyrins reported in Chapter 2 of this dissertation, the
substituents at the 5-position on the dipyrromethane were a 4-phosphonatophenyl diester
and a 4-dimethylaminophenyl. If the substituent at the 5-position could be replaced with a
single proton, then the equilibrium might favor the formation of a single porphyrinogen
species over the formation of scrambled products. While it is true that additional factors
such as concentration of reactants, choice and concentrations of acids, reaction time,
choice of oxidizing agents, and steric and electronic properties of reactants also play a
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role in the condensation reaction, if the effects of scrambling could be minimized, then
this would represent a significant step forward in the preparation of porphyrins.
Given this rationale the preparation of dipyrromethane 3.2 in Scheme 3-1 is an
obvious choice of starting material. Literature procedures for the dipyrromethane’s
preparation have advanced in recent years from the three-step synthetic method used by
Plater 6and Hurley14 to the single step reaction of pyrrole and paraformaldehyde used by
Lindsey.5, 15 It is interesting to note that the use of the Lewis acid, InCl3, in the synthesis
instead of the protic acid, TFA, results in an increase in reported yield from 41-88 %. To
the best of our knowledge, the X-ray structure of dipyrromethane 3.2 has not been
reported in the literature and appears for the first time in this dissertation in Figure 3-1.
In reviewing the successful preparations of porphyrins 3.3 to 3.7 in Scheme 3-1, it
becomes immediately apparent that all aldehydes used were either electron donating (Rb,
Re) or weakly electron withdrawing (Ra, Rc, Re). This trend is contrasted with the
aldehydes used in Scheme 3-2 which are all strongly electron withdrawing (Rf, Rg, Rh)
under acidic conditions. This suggests the benefits of using dipyrromethane 3.2 are only
realized when an electron donating or weakly electron withdrawing aldehyde is employed
in the [2 + 2] reaction. The minimization of acidolytic scrambling by dipyrromethane 3.2
therefore does not override the influence of strongly electron-withdrawing aldehydes
when performing the condensation. In the case of the electron-withdrawing aldehydes,
the reactions did not fail because of acidolytic scrambling; rather, they failed for other
reasons related to the reaction conditions. If they had failed due to acidolytic scrambling,
then, additional porphyrins would have been detected by TLC, UV-Vis, or mass
spectroscopic techniques.
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This electron-donating trend is confirmed in published reports by Senge16, Osuka17,
Plater,6 and Lawrence18 with one exception: Lawrence reported a 73 % yield of 5,15bis(3-nitrophenyl)porphyrin using dipyrromethane 3.2 and 3-nitrobenzaldehyde. To the
best of my knowledge, this is the only reported exception to the general trend. Senge has
reported the synthesis the 5,15-bis(3-nitrophenyl)porphyrin via a mixed aldehyde
condensation, but only in 6 % yield.19 An attempt by Senge to synthesize 5,15-bis(4nitrophenyl)porphyrin via a mixed-aldehyde condensation was unsuccessful.20
The metalation of porphyrins 3.3, 3.4, and 3.7 was brought about using all three
methods outlined in Scheme 3-3; however, Method 36-8 proved to be the best with a yield
of 92 %. Moreover, unlike Methods 1 and 29, Method 3 required only 2 h to complete the
reaction and no chromatography was required to isolate the final product. When Method
1 and 2 were used, a small amount of starting material was always observed in the TLC,
thus requiring column chromatography. Even when excess metal salts were added to the
reaction mixture and the reaction refluxed, this small amount of starting material
persisted. It is believed that the success of Method 3 is due to the use of DMF as a solvent
and the improved solubility of porphyrins and metal salts under refluxing conditions. It is
fortunate that, once cooled, DMF and excess metal salts can be removed by pouring the
reaction into ice water and filtering the pure product. The difficulty encountered with
Method 1 and 2 may be due to the poor solubility of reagents; however, these two
methods may be preferred depending on the thermal stability of some porphyrin
substrates.
The meso-bromination of porphyrins 3.8, 3.9, and 3.10 can be performed according to
literature procedures6, 8, 10, 12 in excellent yield with no column chromatography required
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as shown in Scheme 3-3. In order for the reaction to be successful, it is highly
recommended that the NBS be recrystallized prior to use and that exactly two equivalents
are used in the reaction. If even a small excess is used, bromination at the β-pyrrolic
position will occur. Of all the reactions performed during the course of this dissertation,
the 20 min meso-bromination of porphyrins 3.11, 3.12, and 3.13 was perhaps the easiest.
The demetalation of porphyrins 3.11 and 3.12 proceeded according to a published
method21and resulted in the desired products in near quantitative yield. Porphyrin 3.13
could not be demetalate using the standard TFA method and the use of a stronger acid,
H2SO4, caused the porphyrin to decompose.11 It is unfortunate that a nickel cation was
inserted in the metalation step earlier in the synthesis of porphyrin 3.7 when a zinc cation
would have sufficed and could have been removed without difficulty. The insertion of
nickel was not thought to be a problem at the time and actually proved to be beneficial as
the meso-bromination of porphyrin 3.10 proceeded in 93% yield, which was the highest
yield for all porphyrins brominated. There are many reported cross-coupling reactions of
nickel-metalated porphyrins, and therefore, the inability to remove it does not necessarily
mean that this compound is no longer a useful reagent in further syntheses.16, 22-24
In the first two reactions of Scheme 3-4 an effort was made to synthesize a
carboranylporphyrin with a boronic ester at the 10,20-meso-positions. Had this been
successful, the ester would have been further hydrolyzed, leading to the first known
carboranylporphyrin boronic acid. In theory this reaction should work and there is
literature precedence12, 25-29 to suggest that the synthesis may still be possible, given the
correct reaction conditions.
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Scheme 3-8 illustrates a plausible catalytic cycle for the borylation of the
carboranylporphyrin. Given the fact that the dehalogenated porphyrin 3.8 was recovered
Ar-B(OR)2

Ar-X

Pd(0)

Ar-Pd(II)-B(OR)2

Ar-Pd(II)-X

Et3NH . B(OR)2

Et3NH-X

Et3N + H-B(OR)2

Scheme 3-8: Catalytic Cycle for Borylation of carboranylporphyrin 3.11 27

suggests that the problem with the reaction does not occur in the oxidative addition step,
rather, the problem may reside in the transmetalation step. It is possible that the choice of
an inorganic base such as K2CO3 is preferable to the organic bases, Et3N and pyridine,
used in the reaction. If the proper reaction conditions were found, this compound would
be a valuable intermediate to a host of reactions as well as providing a
carboranylporphyrin with increased boron content.
In the third reaction in Scheme 3-4 an attempt was made to synthesize a mesoborylated carboranylporphyrin via an organolithium intermediate. Admittedly, this
reaction was ambitious and required the formation of a dianionic species as an
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intermediate. Based upon the decomposition of the starting material, this synthetic
method was discontinued.
Scheme 3-5 illustrates another method for the preparation of meso-functionalized
carboranylporphyrin derivatives. Based upon the experience from the previous nbutyllithium chemistry in Scheme 3-4 and literature precedent31-33, an effort was made to
prepare an organolithium ion of the arylhalide in situ, instead of the porphyrin, and then
to react this intermediate with the porphyrin via nucleophilic addition. Once the
nucleophile has added to the porphyrin macrocycle, the reduced porphyrin is then
oxidized to its original aromatic form using DDQ. Scheme 3-9 illustrates the reaction
mechanism. What is interesting to note is that there is no nucleophilic addition of
porphyrin 3.8 which contains the zinc metal; however, there is a nucleophilic addition
involving compound 3.4 which is a metal-free porphyrin.
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It is possible that, unlike the nickel cation in Scheme 3-5, the zinc cation inserted in
compound 3.8 is relatively electron-rich, and therefore inhibits nucleophilic attack. The
successful synthesis of compound 3.16 in 35% opens up the possibility of preparing
highly functionalized asymmetric porphyrins using this method. Further investigation to
determine the scope of this reaction may produce some important compounds which have
application in PDT and BNCT therapies.
Scheme 3-10 below illustrates the Suzuki reaction mechanism employed in Scheme 36, which led to the isolation of carboranylporphyrin 3.18 in 12%. As with the previously

Ar-Ar'

Ar-X

Pd(0)

Ar-Pd(II)-Ar'

Ar-Pd(II)-X

OH
+Cs-O CO
2

B

-

OCO2

Cs2CO3

-Cs+

Ar-Pd(II)-OCO2-Cs+

OH
OH
Ar'

B

-

OCO2-Cs+

OH
Cs2CO3
Ar'B(OH)2

Scheme 3-10: Suzuki Cross-Coupling Reaction Mechanism
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CsX

described borylation reaction mechanism (Scheme 3-8), the reaction proceeds first with
the oxidative addition of the meso-brominated porphyrin 3.15 with the Pd(0) metal,
followed by halogen/base substitution, transmetalation with the quarternized arylboronic
acid, and reductive elimination to yield the final product. As with the borylation reaction,
choice of reaction conditions including catalyst, base, and solvent are important factors
which influence the success of the reaction.
The results from this type of reaction are preliminary at this moment and further
experimentation is warranted. Vicente34 has reported the successful synthesis of
carboranylporphyrins via a Suzuki cross-coupling reaction at the β-pyrrole positions of
the porphyrin in 78% yield using Pd(PPh3)4, toluene, and K2CO3. Hao
similar

success

at

the

5,15-meso-positions

using

35

has reported

5,15-bis-bromo-(3,5-bis-tert-

butylphenyl)porphyrin. Given these reported results, additional research may lead to
promising compounds for application in PDT and BNCT therapies.
The synthesis of 5,10,15,20-tetrakis-(4-phosphenatophenyl)porphyrin (Scheme 3-7)
proceeded according to published literature references.36-38 However, because the standard
Adler-Longo conditions under which the compound is typically synthesized are laborious
due to the presence of large amounts of tar, alternative methods were investigated. Using
TFA under Lindsey conditions proved unsuccessful and no porphyrin product was
obtained. However, when the reaction was performed using the MacDonald [2 + 2]
method and a Lewis acid catalyst instead of propionic acid or TFA, the reaction
progressed in slightly lower yield from the published reports. Acidolytic scrambling was
not an issue since both the dipyrromethane and the aldehyde had the same phosphonate
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diester functionality. At the present time, previously reported literature methods are best
for synthesizing H2TPPP 3.20.
3.4 Conclusion and Future Work
In this chapter an effort was made to investigate alternative routes to symmetric and
asymmetric porphyrins, which would eliminate acidolytic scrambling, excessive column
chromatography, and lead to a single product in high yield. As with many research
projects, additional problems are encountered which were unanticipated. Such is the
nature of chemistry research. In the present chapter, the synthesis of a single porphyrin
product using the MacDonald [2 + 2] method and dipyrromethane 3.2 and an electronrich benzaldehyde was a success. Additional steps to metalate and brominate were also
successful. In each instance the porphyrin was isolated as a single product with no
detectable acidolytic scrambling and without the need for column chromatography. What
was not anticipated was the difficulty in cross-coupling the porphyrin to an aryl species
via a carbon-carbon bond. This problem is not insurmountable, however, as alternatives
to borylations, nucleophilic additions, and Suzuki couplings exist in the form of Heck,
Grignard, Sonogashira, and Stille reactions. These unexplored synthetic avenues may yet
lead to the elusive carbon-carbon formation. As is often the case in research, this chapter
does not represent an end, but rather, a beginning.
3.5 Experimental

•

Dipyrromethane (3.2)5 This compound was synthesized from distilled pyrrole

and paraformaldehyde in a procedure modified from Lindsey et al. Pyrrole 1.5

(100

mL, 1.44 mol) and paraformaldehyde (1.73 g, 0.058 mol) were placed in a 250 mL threenecked RBF fitted with a condenser and heated to 70 oC. While rapidly stirring under
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argon, TFA (0.44 mL, 5.77 mmol) was then syringed into the reaction vessel. After five
minutes the reaction was cooled to 0 oC and unreacted paraformaldehyde was filtered.
Excess pyrrole was removed under reduced pressure. The light green residue was then
dried onto silica and purified by IntelliFlash column chromatography using a gradient

Figure 3-4: Dipyrromethane 3.2 in CD2Cl2 at 250 MHz.
solvent system of 25-40 % CH2Cl2/Hexanes over 10 min, followed by 70 % CH2Cl2. The
title compound was isolated in 28 % yield as a while solid. M.p. = 68.1-69.9 oC (Lit. = 75
o

C); GCMS m/z 145 [M – 1]+; 1H-NMR (CH2Cl2) δ ppm 4.01 (s, 2H, CH2), 6.04 (bs, 2H),

6.15 (m, 2H), 6.71 (m, 2H) and 8.03 (bs, 2H) in close agreement with literature. Note:
Literature values were reported in CDCl3. The H-NMR spectra and the X-ray structure of
compound 3.2 is shown in Figure 3-4 and Figure 3-1, respectively.
General Procedure for the Preparation of 5,15-Bis-substituted-porphyrins (3.3 to
3.7) Dipyrromethane 3.2 (0.28 g, 1.90 mmol), bis[3,5-(2-methyl-o-carboran-1yl)methyl]benzaldehyde 2.3 (0.77 g, 1.73 mmol), and CH2Cl2 (420 mL, 243 mL/mmol)
were added to an oven-dried 1 L RBF and degassed with nitrogen for 15 min. The
reaction vessel was then sealed, evacuated, and covered in foil. TFA (29 µL, 0.38 mmol)
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was added by microliter syringe and the reaction was stirred at rt. for 18 hrs. After
performing a TLC and confirming that all aldehyde was consumed, DDQ (0.589 g, 2.60
mmol) was dissolved in CH2Cl2 and added to the reaction vessel, which stirred was for 30
min. The crude product was then poured directly through a silica gel plug and eluted with
CH2Cl2, or reduced in volume, vacuum filtered, and washed with copious amounts of
CH2Cl2, acetone, or methanol. No further purification was required.
5,15-Bis[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin

(3.3):

This

porphyrin was obtained (0.64 g, 66 % yield) as a reddish/purple solid. M.p.: > 300 oC;
MS (MALDI) m/z 1142.60 [M -1]+; 1H-NMR (CDCl3) δ ppm: -3.14 (br, 2H, NH), 1.3 –
3.4 (br, 40H, BH), 2.27 (s, 12H, CH3), 3.84 (s, 8H, CH2), 7.55 (s, 2H, ArH), 8.14 (s, 4H,
ArH), 9.07 (d, 4H, β-H, J = 4.6 Hz), 9.51 (d, 4H, β-H, J = 4.7 Hz), 10.43 (s, 2H, mesoH) as shown in Figure 3-5. UV-Vis (CHCl3) λmax: 407 nm (ε 388,700), 501 (16,900),
535 (5400), 570 (5500), 625 (1500) in agreement with literature.9, 39 MS (MALDI) m/z
1142.60 [M -1]+; 1H-NMR (CDCl3) δ ppm: -3.14 (br, 2H, NH), 1.3 – 3.4 (br, 40H, BH),
2.27 (s, 12H, CH3), 3.84 (s, 8H, CH2), 7.55 (s, 2H, ArH), 8.14 (s, 4H, ArH), 9.07 (d, 4H,
β-H, J = 4.6 Hz), 9.51 (d, 4H, β-H, J = 4.7 Hz), 10.43 (s, 2H, meso- H) as shown in
Figure 3-5. UV-Vis (CHCl3) λmax: 407 nm (ε 388,700), 501 (16,900),
535 (5400), 570 (5500), 625 (1500) in agreement with literature.9, 39
5,15-Bis(3,5-dimethoxyphenyl)porphyrin (3.4):16 This porphyrin was obtained (124
mg, 51 % yield) as a purple solid. M.p.: > 300 oC; MS (MALDI) m/z 583.25 [M + 1]+;
1

H-NMR (CDCl3) δ ppm: -3.13 (br, 2H, NH), 4.02 (s, 12H, OCH3), 6.96 (bs, 2H, p-ArH),

7.48 (bs, 4H, o-ArH), 9.20 (d, 4H, β-H, J = 4.5 Hz), 9.41 (d, 4H, β-H, J = 4.6 Hz), 10.33
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Figure 3-5: 1H-NMR spectrum of 5,15-Bis[bis-3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.3) in CDCl3 at 300 MHz.
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Figure 3-6: (a) 1H-NMR spectrum of 5,15-Bis(3,5-dimethoxyphenyl)porphyrin (3.4) in
CDCl3 at 300 MHz.

(s, 2H, meso-H) as shown in Figure 3-6. UV-Vis (CHCl3) λmax: 407 nm (ε 229,086), 502
(21,380), 533 (8,511), 573 (8,511), 628 (4,074).

•

5,15-Bis(4-bromophenyl)porphyrin (3.5):19 This porphyrin was obtained (56

mg, 22 % yield) as a purple solid. M.p.: > 300 oC; MS (MALDI) m/z 619 [M - 1]+; 1HNMR (CDCl3) δ ppm: -3.14 (br, 2H, NH), 7.80 (d, 4H, o-ArH, J = 4.6 Hz), 8.17 (d, 4H,
m-ArH, J = 4.6 Hz), 9.08 (d, 4H, β-H, J = 4.6 Hz), 9.44 (d, 4H, β-H, J = 4.6 Hz), 10.37
(s, 2H, meso-H) as shown in Figure 3-7. UV-Vis (CHCl3) λmax: 401 nm (ε 380,189), 494
(16,596), 527 (2,692), 568 (5,129), 621 (468).
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Figure 3-7: 1H-NMR spectrum of 5,15-Bis(4-bromophenyl)porphyrin (3.5) in CDCl3 at
300 MHz.

•

5,15-Bis(4-boronic acid phenyl)porphyrin (3.6): This porphyrin was obtained

(40 mg, 18 % yield) as a purple/brown solid. M.p.: > 300 oC; MS (MALDI) m/z 550 [M
]+; 1H-NMR (CD2Cl2) δ ppm: -3.01 (br, 2H, NH), 7.59 (bs, 4H OH), 8.35 (d, 4H, o-ArH, J
= 8.0 Hz), 8.43 (d, 4H, m-ArH, J = 8.0 Hz), 9.15 (d, 4H, β-H, J = 4.5 Hz), 9.64 (d, 4H,
β-H, J = 4.6 Hz), 10.62 (s, 2H, meso-H). UV-Vis (DMSO) λmax: 408 nm (ε 367,700), 503
(15,797), 538 (8,330), 575 (6,773), 623 (4,394).

•

5,15-Bis-(3,5-bis-tert-butylphenyl)porphyrin

(3.7):6

This

porphyrin

was

obtained (156 mg, 46 % yield) as a purple solid. M.p.: > 300 oC; MS (MALDI) m/z 686
[M ]+; 1H-NMR (CD2Cl2) δ ppm: -3.06 (br, 2H, NH), 1.64 (s, 36H, CH3), 7.91 (t, 4H, pArH, J = 1.8 Hz), 8.19 (d, 4H, o-ArH, J = 1.8 Hz), 9.16 (d, 4H, β-H, J = 4.6 Hz), 9.47 (d,
4H, β-H, J = 4.6 Hz), 10.38 (s, 2H, meso-H) as shown in Figure 3-8. UV-Vis (CH2Cl2)
λmax: 408 nm (ε 347,600), 504 (16,913), 539 (7,284), 576 (6,163), 631 (5,339).
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Figure 3-8: 1H-NMR spectrum (aromatic region only) of 5,15-Bis-(3,5-bis-tertbutylphenyl)porphyrin (3.7) in CD2Cl2 at 250 MHz.

General Procedure for the Metalation of 5,15-Bis-substituted Porphyrins (3.8 to
3.10):

6-8

To a 100 mL RBF was added 5,15-Bis(3,5-dimethoxyphenyl)porphyrin (3.4)

(0.52 g, 0.893 mmol), Zn(OAc)2 • 2H2O (0.500 g, 2.28 mmol), pyridine (0.144 mL, 1.79
mmol), and DMF (30 mL). The solution was heated to reflux while stirring under argon.
After 2 h TLC confirmed the reaction was complete and the reaction was hot filtered by
vacuum filtration in order to remove excess metal salts. The solution was then poured
into ice-cold water at which point a precipitate formed. This precipitate was then vacuum
filtered and washed with either cold MeOH or water. The solids were then removed from
the filter paper and vacuum dried to yield the desired product as a bright pink solid (500
mg, 87 % yield). No further purification was required.
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•

Zn(II)-5,15-bis[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin
9

(3.8):

This porphyrin was obtained (770 mg, 92 % yield) as a bright pink solid. M.p.: > 300 oC;
MS (MALDI) m/z 1206.6 [M ]+; 1H-NMR (CDCl3) δ ppm: 1.4 – 3.0 (br, 40H, BH), 2.25
(s, 12H, CH3), 3.83 (s, 8H, CH2), 7.53 (s, 2H, ArH), 8.12 (s, 4H, ArH), 9.12 (d, 4H, β-H,
J = 4.5 Hz), 9.55 (d, 4H, β-H, J = 4.5 Hz), 10.44 (s, 2H, meso-H) as shown in Figure 3-9.
UV-Vis (CH2Cl2) λmax: 406 nm (ε 389,600), 534 (17,700), 567 (3100).

Figure 3-9: 1H-NMR spectrum of Zn(II)-5,15-bis[bis-3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.8) in CDCl3 at 300 MHz.

•

Zinc (II)-5,15-bis(3,5-dimethoxyphenyl)porphyrin (3.9): This porphyrin was

obtained (340 mg, 85 % yield) as a bright pink solid. M.p.: > 300 oC; MS (MALDI) m/z
643.55 [M-1]+; 1H-NMR (DMSO) δ ppm: 3.96 (s, 12H, CH3), 6.99 (t, 2H, ArH, J = 1.7
Hz), 7.35 (d, 4H, ArH, J = 2.2 Hz), 9.03 (d, 4H, β-H, J = 4.4 Hz), 9.48 (d, 4H, β-H, J =
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4.5 Hz), 10.34 (s, 2H, meso-H) as shown in Figure 3-10. UV-Vis (CH2Cl2) λmax: 412 nm
(ε 346,031), 543 (23,024).

Figure 3-10: 1H-NMR spectrum of Zinc (II)-5,15-Bis(3,5-dimethoxyphenyl)porphyrin
(3.9): in DMSO at 400 MHz.

•

Ni(II)-5,15-bis-(3,5-bis-tert-butylphenyl)porphyrin(3.10): This porphyrin was

obtained (127 mg, 77 % yield) as a red rust-colored solid. M.p.: > 300 oC; MS (MALDI)
m/z 742.54 [M-1]+; 1H-NMR (CD2Cl2) δ ppm: 1.58 (s, 36H, CH3), 7.86 (t, 2H, ArH, J =
1.7 Hz), 7.99 (d, 4H, ArH, J = 1.8 Hz), 9.03 (d, 4H, β-H, J = 4.8 Hz), 9.25 (d, 4H, β-H, J
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= 4.8 Hz), 10.02 (s, 2H, meso-H) as shown in Figure 3-11. UV-Vis (CH2Cl2) λmax: 403 nm
(ε 231,210), 515.75 (17,138), 547 (7,444).

Figure 3-11: 1H-NMR spectrum of Ni (II)-5,15-Bis-(3,5-bis-tert-butylphenyl)porphyrin
(3.10): in CD2Cl2 at 250 MHz.
General Procedure for the meso-Bromination
Metalloporphyrins (3.11 to 3.13):8, 10

of

5,15-bis-substituted

To an oven-dried 500 mL RBF was added Zn(II)-5,15-bis[bis-3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.8) (190 mg, 0.157 mmol), pyridine (25 µL, 0.315
mmol), and CHCl3 (72 mL, 450 mL/mmol). The reaction was cooled to 0 oC and NBS
(56 mg, 0.314 mmol) was manually added to the reaction vessel which was then sealed
and stirred at 0 oC for ten minutes. After performing TLC to confirm that all starting
material was consumed in the reaction, acetone (10 mL) was added to quench the
reaction. After five minutes all solvent was removed under reduced pressure and the
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crude product was sonicated in MeOH and vacuum filtered. The final product was
obtained as a red/purple solid (184 mg, 86 % yield). No further purification was required.
(Note: Prior to the addition of pyridine, the solids are poorly soluble in CHCl3.
Additionally, NBS was recrystallized from water and dried with cold MeOH prior to
use.)

Figure 3-12: 1H-NMR spectrum of Zn(II)-5,15-bis-bromo[bis-3,5-(1-methyl-ocarboranyl)methylphenyl]porphyrin (3.11) in DMSO at 300 MHz.

•
Zn(II)-5,15-bis-bromo[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]
porphyrin (3.11):
This porphyrin was obtained (184 mg, 86 % yield) as a purple/red solid. M.p.: > 300 oC;
MS (MALDI) m/z 1364.2 [M ]+; 1H-NMR (DMSO) δ ppm: 2.33 (s, 12H, CH3), 4.03 (s,
8H, CH2), 7.75 (bs, 2H, ArH), 8.10 (s, 4H, ArH), 8.84 (d, 4H, β-H, J = 4.7 Hz), 9.71 (d,
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4H, β-H, J = 4.7 Hz) as shown in Figure 3-12. UV-Vis (THF) λmax: 424 nm (ε 309,934),
565 (18,812), 604 (10,418).

•

Zinc(II)-5,15-bis-bromo-10,20-(3,5-dimethoxyphenyl)porphyrin(3.12):

This porphyrin was obtained (479 mg, 77 % yield) as a purple solid. M.p.: > 300 oC; MS
(MALDI) m/z 803 [M ]+; 1H-NMR (CD2Cl2) δ ppm: 3.93 (s, 12H, CH2), 6.95 (t, 2H, ArH,
J = 2.6 Hz), 7.37 (d, 4H, ArH, J = 2.1), 9.07 (d, 4H, β-H, J = 4.7 Hz), 9.75 (d, 4H, β-H, J
= 4.7 Hz as shown in Figure 3-13. UV-Vis (DMSO) λmax: 423 nm (ε 321,703), 568
(22,618), 609 (14,663).

Figure 3-13: 1H-NMR spectrum of Zinc(II)-5,15-bis-bromo-10,20-(3,5dimethoxyphenyl)porphyrin (3.12) in DMSO at 250 MHz.

•

Ni(II)-5,15-bis-bromo-10,20-(3,5-bis-tert-butylphenyl)porphyrin(3.13):

This porphyrin was obtained (131 mg, 93 % yield) as a red solid. M.p.: > 300 oC; MS
(MALDI) m/z 901.2 [M ]+; 1H-NMR (CD2Cl2) δ ppm: 1.58 (s, 36H, CH3), 7.86 (t, 2H,
ArH, J = 1.7 Hz), 7.99 (d, 4H, ArH, J = 1.8 Hz), 9.03 (d, 4H, β-H, J = 4.8 Hz), 9.25 (d,
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4H, β-H, J = 4.8 Hz), 10.02 (s, 2H, meso-H) as shown in Figure 3-14. UV-Vis (CH2Cl2)
λmax: 422 nm (ε 286,341), 537 (16,477).

Figure 3-14: 1H-NMR spectrum of Ni(II)-5,15-bis-bromo-10,20-(3,5-bis-tertbutylphenyl)porphyrin(3.13) in CD2Cl2 at 250 MHz.

General Procedure for the Demetalation of Zinc(II)-5,15-bis-substituted Porphyrins
(3.14 and 3.15): To an oven-dried 50 mL RBF was added Zinc(II)-5,15-bis-bromo-10,20(3,5-dimethoxyphenyl)porphyrin (3.12) (125 mg, 0.154 mmol), CH2Cl2 (15 mL), TFA (4
mL, 41 mmol), and stirred overnight at rt. The metalated porphyrin is initially red, then
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turns green upon addition of TFA which improves its solubility. The next day, the
reaction was vacuum filtered and transferred to a separatory funnel. CH2Cl2 (100 mL) was
added and the organic phase was washed with water, brine, dried over Na2SO4, filtered,
and the solvent removed by vacuum distillation to yield an iridescent purple product (121
mg, >99 % yield). No further purification was required.

•

5,15-bis-bromo[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin

(3.14):
This porphyrin was obtained (130 mg, 97 % yield) as a red solid. M.p.: > 300 oC; MS
(MALDI) m/z 1302.8 [M + 1]+; 1H-NMR (CD2Cl2) δ ppm: -3.94 (s, 2H, NH), 2.35 (s,
12H, CH3), 3.91 (s, 8H, CH2), 7.72 (bs, 2H, ArH), 8.33 (bs, 4H, ArH), 8.56 (bs, 4H, β-H),
9.32 (bs, 4H, β-H). UV-Vis (CH2Cl2) λmax: 424 nm (ε 240,610), 548 (14,493), 576
(6,046), 616 (4,442), 668 (3,797).

•

5,15-Bis-bromo-10,20-bis-(3,5-dimethoxyphenyl)porphyrin (3.15):

This porphyrin was obtained (121 mg, >99 % yield) as a purple solid. M.p.: > 300 oC; MS
(MALDI) m/z 739.2 [M - 1]+; 1H-NMR (CD2Cl2) δ ppm: -2.76 (bs 2H, NH), 4.01 (s, 12H,
CH3), 6.96 (t, 2H, ArH, J = 2.2 Hz), 7.37 (d, 4H, ArH, J = 2.3), 9.00 (d, 4H, β-H, J = 4.9
Hz), 9.66 (d, 4H, β-H, J = 4.9 Hz) as shown in Figure 3-15. UV-Vis (CH2Cl2) λmax: 423
nm (ε 322,641), 520 (11,663), 555 (6,721), 599 (4,143), 657 (3,783).

•
5-(4-Dimethylaminophenyl)-10,20-bis-(3,5-dimethoxyphenyl)porphyrin
(3.16):31-33
A Schlenk flask was charged with 4-Bromo-N,N-dimethylaniline (454 mg, 2.27 mmol),
diethylether (10 mL), and alternately evacuated and purged with nitrogen, then cooled to
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Figure 3-15: 1H-NMR spectrum of 5,15-Bis-bromo-10,20-bis-(3,5dimethoxyphenyl)porphyrin (3.15) in DMSO at 300 MHz.
-78 oC whereupon (2.5 M in hexanes) n-BuLi (0.913 mL, 2.27 mmol) was slowly added
by syringe. The reaction was allowed to warm to rt and stir for one hour. The solution
gradually turns light yellow and cloudy. 5,15-Bis(3,5-dimethoxyphenyl)porphyrin (3.4)
(60 mg, 0.103 mmol) was dissolved in anhydrous THF and cooled to -40 oC and added to
the lithiated aniline via syringe. Prior to addition, the lithiated aniline was cooled to -40
o

C. The reaction turns purple/brown immediately. After stirring for 30 min a 1:1 solution

of water/THF was added to the reaction vessel. The reaction immediately turned from a
brown/dark green to a blue/green color. After stirring for 20 min, DDQ (585 mg, 2.58
mmol) dissolved in 43 mL of CH2Cl2 was added to the reaction. After stirring an
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additional 30 min the solvent was removed under reduced pressure and the crude was
taken up in a minimal amount of CH2Cl2 and passed through a column of silica gel using
CH2Cl2 as a solvent. The crude material was further purified using alumina preparatory
plates and a solvent system consisting of 1:1 hexanes/ CH2Cl2. The final product was
obtained as a purple/red solid (25 mg, 35% yield) after recrystallization in MeOH/CHCl3.
M.p.: > 300 oC; MS (MALDI) m/z 702.3 [M + 1]+; 1H-NMR (CD2Cl2) δ ppm: -3.05 (bs
2H, NH), 3.25 (s, 6H, N(CH3)2), 4.00 (s, 12H, OCH3), 6.95 (t, 2H, p-ArH, J = 4.6 Hz),
7.14 (d, 2H, ArH, J = 4.6), 7.45 (bs, 4H, ArH), 8.10 (d, 2H, o-ArH, J = 3.0), 9.00 (bs,
4H, β-H), 9.13 (d, 2H, β-H, J = 4.7 Hz), 9.37 (d, 2H, β-H, J = 4.7 Hz), 10.21 (s, 1H,
meso-H). UV-Vis (CH2Cl2) λmax: 413 nm (ε 266,390), 511 (14,724), 548 (7,960), 584
(6,821), 642 (4,288).

•

3,5-Bis(1-methyl-o-carboranyl)methylphenylboronic acid (3.17):30

To a solution of 3,5-Bis(1-methyl-o-carboranyl)methylphenylbromide (100 mg, 0.201
mmol) in anhydrous THF (3 mL) at -78 oC under nitrogen was added drop-wise a 2.5 M
solution of n-BuLi (87 µL, 0.221 mmol) in hexanes. The reaction turned bright yellow.
The reaction mixture was stirred at -78 oC for 30 min before trimethylborate (68 µL,
0.603 mmol) was added and the mixture stirred for an additional 30 min at -78 oC. The
subsequent reaction mixture was then allowed to warm to rt before being acidified with
aqueous 10 % HCl. Extraction of the organic material into CH2Cl2 (3X 100 mL) was
followed by drying the organic layer (Na2SO4), filtering, before being concentrated under
reduced pressure to give the title compound 3.2 as a white solid (69 mg, 74 % yield). No
further purification was required. M.p.: 110-111 oC; MS (MALDI) m/z 461.7 [M - 1]+;
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1

H-NMR (CD2Cl2) δ ppm: 1.4-3.1 (br, 20H, BH), 2.29 (s, 6H, CH3), 3.55 (d, 2H, OH, J =

3.0 Hz), 3.67 (s, 4H, CH2), 7.33 (s, 1H, p-ArH), 8.08 (s, 2H, o-ArH).

•

5,15-Bis-(3,5-dimethoxyphenyl)-10-[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin (3.18):
This porphyrin was obtained (6 mg, 12 % yield) as a red solid. M.p.: > 300 oC; MS
(MALDI) m/z 1002.1 [M + 1]+; 1H-NMR (CD2Cl2) δ ppm: 0.5- 2.3 (br, 20H, BH), 2.18
(s, 6H, CH3), 3.44 (s, 12H, OCH3), 4.01 (bs, 4H, CH2), 6.69 (s, 1H), 6.70 (s, 2H), 6.97
(bs, 2H), 7.48 (bs, 4H), 9.21 (bs, 4H, β-H), 9.46 (bs, 4H, β-H), 10.38 (s, 1H, meso-H);
UV-Vis (CH2Cl2) λmax: 410 nm (ε 259,974), 505 (13,746), 540 (6,817), 579 (6,587), 633
(4,195).

•

5,10,15,20-Tetrakis(4-phosphenatophenyl)porphyrin octaethyl ester (3.19)38:

A solution of diethyl 4-formylphenylphosphonate (2.00 g, 8.3 mmol) and pyrrole (0.55
mL, 8.0 mmol) in 30 mL of propionic acid was refluxed in a flask protected from light
for 2h. The mixture was evaporated to dryness and purified by column chromatography
on neutral alumina eluting with dichloromethane-methanol (98.5 : 1.5) to yield the title
compound 3.19 (68 mg, 6 %) as a purple solid. M.p.: > 300 oC; MS (MALDI) m/z 1161
[M + 1]+; 1H-NMR (CD2Cl2) δ ppm: -2.83 (brs, 2H, NH), 1.52 (t, 24H, J = 6.9 Hz, CH3)
4.36 (m, 16H, OCH2), 8.23 (m, 8H, m-CH), 8.36 (m, 8H, o-CH) 8.90 (s, 8H, β-H) as
shown in Figure 3-16; UV-Vis (CH2Cl2) λmax: 419 nm (ε 271,337), 515 (16,310), 550
(6,990), 589 (6,786), 645 (5,122).
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Figure 3-16: 1H-NMR spectrum of 5,10,15,20-Tetrakis(4-phosphenatophenyl)porphyrin
octaethyl ester (3.19) in CD2Cl2 at 250 MHz.

•

5,10,15,20-Tetrakis(4-phosphenatophenyl)porphyrin, TPPP, (3.20)36-38:

A 50 mL RBF was charged with 5,10,15,20-Tetrakis(4-phosphenatophenyl)porphyrin
octaethyl ester (3.19) (66 mg, 0.057 mmol), dichloromethane (6 mL) and purged with
nitrogen. Bromotimethylsilane (TMSBr) (0.47 mL, 3.64 mmol) was added by syringe and
the covered reaction allowed to stir for 24 hrs at rt. The purple solution turns green upon
addition of TMSBr. After 24 hrs TLC confirms that silylation is complete whereupon the
solvent and TMSBr were removed under reduced pressure. A 1:1 H2O/MeOH solution
and 0.5 mL of concentrated HCl were then added and the reaction allowed to stir for an
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additional 24 hrs. The precipitate which formed was washed with water and dried under
high vacuum to yield the title compound (3.20) (50 mg, 94 %) as a blue/green solid.
M.p.: > 310 oC; MS (MALDI) m/z 935 [M + 1]+; 1H-NMR (DMSO) δ ppm: -2.99 (brs,
2H, NH), 8.11 (m, 8H, m-CH), 8.30 (m, 8H, o-CH) 8.82 (s, 8H, β-H); UV-Vis (DMSO)
λmax: 419 nm (ε 266,552), 516 (16,930), 550 (7,217), 590 (6,882), 646 (4,775).
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Chapter 4
In Vitro Biological Evaluation of Trimethylamine- and Phosphonate-substituted
Carboranylporphyrins for Application in BNCT
4.1 Introduction
Boron neutron capture therapy (BNCT) is a binary therapy that involves the activation of
a tumor-localized

10

B-containing sensitizer with low energy neutrons, resulting in the

release of high linear energy transfer (high-LET) particles (4He2+ and 7Li3+) containing 2.4
MeV of kinetic energy.1-3 The short-range high-LET particles are highly cytotoxic and
thus can selectively destroy 10B-containing malignant cells in the presence of boron-free
normal tissues. BNCT is particularly attractive for the treatment of high-grade gliomas,
malignant melanomas, meningiomas, head and neck tumors, and oral cancer.4 Two
boron-containing

compounds,

mercapto-closo-dodecaborate

(BSH)

and

4-

dihydroxyborylphenylalanine (BPA), are currently being used in BNCT clinical trials, in
the USA, Europe and Japan.4-9 Since in the clinical studies performed to date there has
been evidence of a therapeutic response to BNCT, the discovery of BNCT agents with
higher biological efficacy than BSH and BPA has been an active area of research. Several
boron-containing molecules have been synthesized and investigated as boron delivery
agents for BNCT, including nucleosides, amino acids, phospholipids, monoclonal
antibodies, dendrimers and porphyrins.10, 11 Among these, porphyrins are very promising
boron delivery vehicles because of their known tumor selectivity, low dark toxicity and
long persistence within tumors.12, 13 A promising BNCT delivery porphyrin agent should
exhibit the following characteristics: (1) low dark toxicity, (2) high tumor cell selectivity,
i.e. high tumor/normal tissue and tumor/blood boron concentration ratios, (3) deliver
therapeutic concentrations of 10B to tumors, i.e. > 20 mg 10B/g tumor,4 (4) localize within
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tumor cells, preferentially within or near sensitive organelles such as nuclei,14, 15 (5) have
long retention times within tumors and rapid clearance from normal tissues and blood,
and (6) be easily monitored by fluorescence techniques in order to facilitate radiation
dosimetry. The major challenge in the development of BNCT delivery agents has been
the selective delivery of therapeutic amounts of boron to targeted tumors with minimal
normal tissue toxicity.4

Figure 4-1: Dark cytotoxicity of porphyrins 2.6c (purple), 2.6d (black), 2.7c (blue),
2.7d (red) and 2.8d (green)
4.2 Dark Cytotoxicity
The dark toxicity of porphyrins 2.6c, 2.6d, 2.7c, 2.7d and 2.8d toward human
carcinoma HEp2 cells was evaluated at concentrations up to 100 mM and the results
obtained are shown in Figure 4-1. All compounds were found to be non-toxic to
HEp2 cells in the dark under the conditions tested, up to 100 mM concentrations.
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4.3 Cellular Uptake
The time-dependent uptake of porphyrins 2.6c, 2.6d, 2.7c, 2.7d and 2.8d was
evaluated in human glioblastoma T98G cells at a concentration of 10 µM over a
period of 24 h and the results are shown in Figure 4-2. All porphyrins accumulated
rapidly in the first 2 h, after which a plateau was reached for 2.6c, 2.6d, 2.7c and
2.7d, while 2.8d continued to steadily accumulate over time up to the 24 h period
investigated. Porphyrin 2.6c bearing two quaternary ammonium groups on adjacent pphenyl positions accumulated the most of this series compounds at short time points
(< 4 h) while porphyrin 2.8d with three phosphonic acid groups, accumulated the
most at longer time points (> 8 h). Porphyrin 2.7c containing only one quaternary
ammonium group was the least taken-up by the T98G cells at all time points
investigated. Similar uptake results were also obtained using human carcinoma HEp2
cells (results not shown).
4.4 Intracellular Localization
Fluorescence microscopy was used to investigate the preferential sites of intracellular
localization of porphyrins 2.6c, 2.6d, 2.7c, 2.7d and 2.8d, using both HEp2 and
T98G cells. The cells were exposed overnight to 10 µM of each porphyrin and then
examined for intracellular fluorescence. Similar results were obtained with both cell
lines; Figures 4-3 to 4-7 show the fluorescence patterns observed in HEp2 cells. For
the co-localization experiments the cells were incubated concurrently with porphyrin
and one of the following organelle tracers for 30 min: MitoTracker Green 250 nM,
LysoSensor Green, BODIPY FL C5 -ceramide at 50 nM and 50 nM, DiOC6 5 µg/mL.
The slides were washed three times with growth medium and new medium
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containing 50 mM HEPES pH 7.4 was added. The images were acquired using a
Zeiss Axiovert 200M inverted fluorescent microscope fitted with standard FITC and
Texas Red filter sets. The preferential site of intracellular localization for porphyrins
2.6c-2.6d, 2.7c-2.d, and 2.8d was found to be the lysosomes (Figures 4-3f to 4-7f).

Figure 4-2: Time-dependent uptake of porphyrins 2.6c (purple), 2.6d (black), 2.7c
(blue), 2.7d (red) and 2.8d (green)

4.5 Discussion
Porphyrins 2.6c, 2.6d, 2.7c, 2.7d and 2.8d were all found to be non-toxic to HEp2
cells in the dark up to 100 mM concentrations (Figure 4-1). Higher concentrations
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Figure 4-3: Intracellular localization of porphyrin 2.6c in HEp2 cells at 10 µM for 24 h.
(a) phase contrast; (b) porphyrin fluorescence; (c) BODIPY FL- C5-Ceramide
fluorescence (Golgi label); (d) overlay with porphyrin; (e) LysoSensor fluorescence
(lysosome label); f: overlay; (g) MitoTracker fluorescence (mitochondria label); (h)
overlay; (i) ERTracker Green FM fluorescence (ER label); (j) overlay. Scale bar: 10 µm.
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Figure 4-4: Intracellular localization of porphyrin 2.6d in HEp2 cells at 10 µM for 24 h.
(a) phase contrast; (b) porphyrin fluorescence; (c) BODIPY FL- C5-Ceramide
fluorescence (Golgi label); (d) overlay with porphyrin; (e) LysoSensor fluorescence
(lysosome label); f: overlay; (g) MitoTracker fluorescence (mitochondria label); (h)
overlay; (i) ERTracker Green FM fluorescence (ER label); (j) overlay. Scale bar: 10 µm.
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Figure 4-5: Intracellular localization of porphyrin 2.7c in HEp2 cells at 10 µM for 24 h.
(a) phase contrast; (b) porphyrin fluorescence; (c) BODIPY FL- C5-Ceramide
fluorescence (Golgi label); (d) overlay with porphyrin; (e) LysoSensor fluorescence
(lysosome label); f: overlay; (g) MitoTracker fluorescence (mitochondria label); (h)
overlay; (i) ERTracker Green FM fluorescence (ER label); (j) overlay. Scale bar: 10 µm.
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Figure 4-6: Intracellular localization of porphyrin 2.7d in HEp2 cells at 10 µM for 24 h.
(a) phase contrast; (b) porphyrin fluorescence; (c) BODIPY FL- C5-Ceramide
fluorescence (Golgi label); (d) overlay with porphyrin; (e) LysoSensor fluorescence
(lysosome label); f: overlay; (g) MitoTracker fluorescence (mitochondria label); (h)
overlay; (i) ERTracker Green FM fluorescence (ER label); (j) overlay. Scale bar: 10 µm.
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Figure 4-7: Intracellular localization of porphyrin 2.8d in HEp2 cells at 10 µM for 24 h.
(a) phase contrast; (b) porphyrin fluorescence; (c) BODIPY FL- C5-Ceramide
fluorescence (Golgi label); (d) overlay with porphyrin; (e) LysoSensor fluorescence
(lysosome label); f: overlay; (g) MitoTracker fluorescence (mitochondria label); (h)
overlay; (i) ERTracker Green FM fluorescence (ER label); (j) overlay. Scale bar: 10 µm.
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were not investigated because the compounds precipitated. Our results are in agreement
with previous studies reporting very low dark toxicities for both closo- and nidocarboranylporphyrins.16-24The cellular uptake of this series of closo-carboranylporphyrins
did not increase with their hydrophobic character. We determined the following order of
increasing uptake at times < 8 h: 2.6c > 2.8d > 2.7d > 2.6d > 2.7c (Figure 4-2). At longer
time periods porphyrin 2.8d, bearing three phosphonic acid groups, was the most
accumulated within cells, and at 24 h twice the amount of this porphyrin was found
within cells than 2.6d, containing two phosphonic acid groups on adjacent phenyl rings.
Porphyrin 2.7d with only one phosphonic acid substituent showed slightly higher uptake
than 2.6d at all time points investigated. These results might be due to the unique
aggregation behavior of these polyprotic compounds, as we have previously
investigated.25 At physiologic pH the phosphonic acid groups mainly exist in their monoanionic form (i.e. as PO3H-) and the resulting anionic porphyrins can aggregate as a result
of both p-p interactions and hydrogen bond formation. It has been recently shown that
negatively charged cobaltacarborane-porphyrins containing up to eight negative charges
form large aggregates in aqueous solutions.26, 27 On the other hand porphyrin 2.6c, bearing
two ammonium groups accumulated within T98G cells about 2.5 times more than 2.7c
with only one positive charge; in fact porphyrin 2.7c was the least taken up by cells of all
the porphyrins studied. The higher amphiphilicity of porphyrin 2.6c as a result of its more
favorable lipophilic/hydrophilic balance as a consequence of its charge distribution might
be responsible for the observed results. The uptake kinetics for this series of
carboranylporphyrins is similar to that previously observed for both closo- and nidocarboranylporphyrins.20, 22, 24, 27-29
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The preferential sites of intracellular localization for porphyrins 2.6c, 2.6d, 2.7c, 2.7d
and 2.8d were found to be the cell lysosomes, as evidenced by the punctate pattern
observed by fluorescence microscopy and its overlay with the lysosome-specific probe
Lysotracker Green. These results are in agreement with previous studies showing that
carboranylporphyrins localize within cell lysosomes,20, 24, 27, 28, 30-32 maybe as a result of an
endocytic mechanism of uptake.33, 34
4.6 Conclusions
All porphyrins were found to be non-toxic in the dark up to 100 mM concentrations and
the extent of their cellular uptake did not increase with their hydrophobic character. The
tetracarboranylporphyrin 2.6c, bearing two quaternary ammonium groups, was the most
efficiently taken up by human glioma T98G cells at short times (up to 8 h), followed by
dicarboranylporphyrin 2.8d bearing three phosphonic acid substituents. The preferential
sites of subcellular localization for all porphyrins were found to be the cell lysosomes.
4.7 Experimental
The trimethylamine- and phosphonate-substituted carboranylporphyrins discussed in this
chapter were evaluated in in vitro by Mr. Tim Jensen in the Life Sciences Building at
Louisiana State University in Baton Rouge, Louisiana.
4.7.1 Cell Culture
HEp2 and T98G cells were acquired from the ATCC and maintained in a 50:50 mix of
Advanced MEM:DMEM supplemented with 5% FBS (all from Invitrogen). The cultures
were passaged twice weekly to maintain sub confluent stocks. Each porphyrin was
prepared as a 10 mM stock in DMSO and diluted to a working concentration of 10 µM in
two stages. First, equal volumes of 10 mM stock and Cremophor EL (Fluka) were mixed

127

in a microfuge tube and sonicated using a bath sonicator for 10 min. This mixture was
then diluted with DMSO to a final porphyrin concentration of 1 mM. This was then
diluted by drop wise addition of medium to give a final concentration of 10 µM. The
medium-containing porphyrin was then sonicated for 30 min.
4.7.2 Dark Cytotoxicity
HEp2 cells were plated as described above and allowed 36 – 48 h to attach. The cells
were then exposed to various concentrations of porphyrin up to 100 µM and incubated
overnight. The loading medium was supplemented with CellTitre Blue (Promega) as per
manufacturer’s instructions. Cell viability was measured by reading the fluorescence at
520/584nm using a BMG FLUOstar plate reader. The signal was normalized to 100%
viable (untreated cells) and 0% viable (cells treated with 0.2% saponin (Sigma).
4.7.3 Time-dependent Cellular Uptake
T98G cells were plated at 20000 per well in a Costar 96 well plate and allowed to grow
36 h. Porphyrin stocks were prepared as above to 2x stocks. The porphyrin was then
diluted in medium to final working concentrations. The cells were exposed to 10µM
porphyrin for 0, 1, 2, 4, 8, and 24 h. The uptake was stopped by removing the loading
medium and by washing the cells with PBS. The cells were solubilized by the addition of
100 µl of 0.25% Triton X-100 (Calbiochem) in PBS. To determine compound
concentration, fluorescence emission was read at 410/650 nm (excitation/emission) using
a BMG FLUOstar plate reader. The cell numbers were quantified using CyQuant reagent
(Molecular Probes).
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4.7.4 Intracellular Localization
HEp2 cells were plated on LabTek II two chamber cover slips and incubated 36 h. The
cells were then exposed to 10 µM of each porphyrin for 24 h. For co-localization
experiments using organelle tracers, cells were incubated concurrently with compound
the following morning for 30 min with the following organelle tracers: Mitochondria:
MitoTracker Green (Molecular Probes) 250 nM; Lysosomes: LysoSensor Green
(Molecular Probes) 50 nM; Endoplasmic reticulum: ERTracker Green FM (Molecular
Probes) 2 µg/ml (for 1 h); Golgi: BODIPY FL- C5-Ceramide (Molecular Probes) 1 mM.
The slides were washed three times with growth medium and fed medium containing 50
mM HEPES pH 7.4. Fluorescent microscopy was performed using a Zeiss Labovert
200M inverted fluorescent microscope fitted with a standard FITC filter set (Ex/Em
470nm/540nm) for organelle tracers and standard Texas Red filter set (560nm/600 nm
LP) set for compound detection (Chroma). The images were acquired with a Zeiss
Axiocam MRM CCD camera fitted to the microscope.
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